{
  "$schema": "folio-library-document/v1",
  "id": "10665-352522",
  "title": "WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents",
  "variant": "pdf",
  "pages": 128,
  "tocSource": "outline",
  "tocMethod": null,
  "toc": [
    {
      "level": 1,
      "title": "Acknowledgements",
      "number": null,
      "page": 7,
      "pageLabel": "v",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-000-acknowledgements"
    },
    {
      "level": 1,
      "title": "Abbreviations",
      "number": null,
      "page": 11,
      "pageLabel": "ix",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-001-abbreviations"
    },
    {
      "level": 1,
      "title": "Definitions",
      "number": null,
      "page": 13,
      "pageLabel": "xi",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-002-definitions"
    },
    {
      "level": 1,
      "title": "Executive summary",
      "number": null,
      "page": 19,
      "pageLabel": "xvii",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-003-executive-summary"
    },
    {
      "level": 1,
      "title": "Introduction",
      "number": "1",
      "page": 25,
      "pageLabel": "1",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-004-1-introduction"
    },
    {
      "level": 2,
      "title": "Background",
      "number": "1.1",
      "page": 25,
      "pageLabel": "1",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-005-11-background"
    },
    {
      "level": 2,
      "title": "Rationale for the development of the 2022 consolidated guidelines",
      "number": "1.2",
      "page": 26,
      "pageLabel": "2",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-006-12-rationale-for-the-development-of-the-2022-con"
    },
    {
      "level": 2,
      "title": "Objectives of the 2022 consolidated guidelines",
      "number": "1.3",
      "page": 26,
      "pageLabel": "2",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-007-13-objectives-of-the-2022-consolidated-guideline"
    },
    {
      "level": 2,
      "title": "Target audience",
      "number": "1.4",
      "page": 26,
      "pageLabel": "2",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-008-14-target-audience"
    },
    {
      "level": 2,
      "title": "WHO recommendations relevant to the management of TB in children and adolescents",
      "number": "1.5",
      "page": 26,
      "pageLabel": "2",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-009-15-who-recommendations-relevant-to-the-managemen"
    },
    {
      "level": 2,
      "title": "Scope of the guideline update",
      "number": "1.6",
      "page": 27,
      "pageLabel": "3",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-010-16-scope-of-the-guideline-update"
    },
    {
      "level": 2,
      "title": "Publication, dissemination, evaluation and expiry",
      "number": "1.7",
      "page": 30,
      "pageLabel": "6",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-011-17-publication-dissemination-evaluation-and-expi"
    },
    {
      "level": 2,
      "title": "Document structure",
      "number": "1.8",
      "page": 30,
      "pageLabel": "6",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-012-18-document-structure"
    },
    {
      "level": 1,
      "title": "TB screening and contact investigation",
      "number": "2",
      "page": 33,
      "pageLabel": "9",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-013-2-tb-screening-and-contact-investigation"
    },
    {
      "level": 1,
      "title": "Prevention of TB",
      "number": "3",
      "page": 35,
      "pageLabel": "11",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-014-3-prevention-of-tb"
    },
    {
      "level": 1,
      "title": "Diagnostic approaches for TB in children and adolescents",
      "number": "4",
      "page": 41,
      "pageLabel": "17",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-015-4-diagnostic-approaches-for-tb-in-children-and-a"
    },
    {
      "level": 2,
      "title": "The use of the Xpert MTB/RIF Ultra assay in gastric aspirate and stool specimens for the diagnosis of pulmonary TB and rifampicin resistance",
      "number": "4.1",
      "page": 42,
      "pageLabel": "18",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-016-41-the-use-of-the-xpert-mtbrif-ultra-assay-in-ga"
    },
    {
      "level": 2,
      "title": "Treatment decision algorithms for the diagnosis of pulmonary TB in children aged below 10 years of age",
      "number": "4.2",
      "page": 46,
      "pageLabel": "22",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-017-42-treatment-decision-algorithms-for-the-diagnos"
    },
    {
      "level": 2,
      "title": "Consolidated recommendations on TB diagnostics and diagnostic approaches relevant to children and adolescents",
      "number": "4.3",
      "page": 50,
      "pageLabel": "26",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-018-43-consolidated-recommendations-on-tb-diagnostic"
    },
    {
      "level": 1,
      "title": "Treatment of TB disease in children and adolescents",
      "number": "5",
      "page": 55,
      "pageLabel": "31",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-019-5-treatment-of-tb-disease-in-children-and-adoles"
    },
    {
      "level": 2,
      "title": "Treatment shortening in children and adolescents with non-severe TB",
      "number": "5.1",
      "page": 56,
      "pageLabel": "32",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-020-51-treatment-shortening-in-children-and-adolesce"
    },
    {
      "level": 2,
      "title": "Treatment regimens for TB meningitis in children and adolescents",
      "number": "5.2",
      "page": 61,
      "pageLabel": "37",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-021-52-treatment-regimens-for-tb-meningitis-in-child"
    },
    {
      "level": 2,
      "title": "Treatment of multi-drug and rifampicin resistant TB in children",
      "number": "5.3",
      "page": 65,
      "pageLabel": "41",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-022-53-treatment-of-multi-drug-and-rifampicin-resist"
    },
    {
      "level": 2,
      "title": "Consolidated recommendations on TB treatment for children and adolescents",
      "number": "5.4",
      "page": 77,
      "pageLabel": "53",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-023-54-consolidated-recommendations-on-tb-treatment"
    },
    {
      "level": 1,
      "title": "Models of TB care for case detection and provision of TPT in children and adolescents",
      "number": "6",
      "page": 81,
      "pageLabel": "57",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-024-6-models-of-tb-care-for-case-detection-and-provi"
    },
    {
      "level": 2,
      "title": "Decentralized and family-centred, integrated models of care to deliver child and adolescent TB services",
      "number": "6.1",
      "page": 82,
      "pageLabel": "58",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-025-61-decentralized-and-family-centred-integrated-m"
    },
    {
      "level": 2,
      "title": "Consolidated recommendations on models of TB care relevant to children and adolescents",
      "number": "6.2",
      "page": 87,
      "pageLabel": "63",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-026-62-consolidated-recommendations-on-models-of-tb"
    },
    {
      "level": 1,
      "title": "Special situations",
      "number": "7",
      "page": 89,
      "pageLabel": "65",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-027-7-special-situations"
    },
    {
      "level": 1,
      "title": "Research priorities",
      "number": "8",
      "page": 93,
      "pageLabel": "69",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-028-8-research-priorities"
    },
    {
      "level": 1,
      "title": "References",
      "number": "9",
      "page": 97,
      "pageLabel": "73",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-029-9-references"
    },
    {
      "level": 1,
      "title": "Annex 1. WHO recommendations incorporated in the guidelines on the management of TB in children and adolescents",
      "number": null,
      "page": 105,
      "pageLabel": "81",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-030-annex-1-who-recommendations-incorporated-in-the"
    },
    {
      "level": 1,
      "title": "Annex 2. Supplementary table",
      "number": null,
      "page": 107,
      "pageLabel": "83",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-031-annex-2-supplementary-table"
    },
    {
      "level": 2,
      "title": "Summary of changes to recommendations as included in the second edition of the Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2014",
      "number": null,
      "page": 107,
      "pageLabel": "83",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-032-summary-of-changes-to-recommendations-as-include"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 7,
      "labelStart": "a",
      "labelEnd": "v",
      "words": 877,
      "summary": {
        "text": "The front matter of the WHO consolidated tuberculosis guidelines, Module 5 on managing tuberculosis in children and adolescents (2022), with ISBNs, licence terms, contents and links to web annexes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "consolidated recommendations",
          "heading": false
        },
        {
          "term": "consolidated guidelines",
          "heading": false
        },
        {
          "term": "web annex",
          "heading": false
        },
        {
          "term": "creative commons",
          "heading": false
        },
        {
          "term": "adolescents",
          "heading": false
        },
        {
          "term": "children",
          "heading": false
        },
        {
          "term": "suggested citation",
          "heading": false
        },
        {
          "term": "licence",
          "heading": false
        }
      ],
      "extract": "WHO consolidated guidelines on tuberculosis Module 5: Management of tuberculosis in children and adolescents WHO \u0003consolidated guidelines on\u0003 tuberculosis Module 5: Management of tuberculosis in children and adolescents WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents ISBN 978–92–4-004676–4 (electronic version) ISBN 978–92–4-004677–1 (print version) ©",
      "extractCut": true,
      "blocks": [
        "library/10665-352522/blocks/prose-sec-front-matter"
      ]
    },
    {
      "id": "sec-000-acknowledgements",
      "number": null,
      "title": "Acknowledgements",
      "level": 1,
      "pageStart": 7,
      "pageEnd": 11,
      "labelStart": "v",
      "labelEnd": "ix",
      "words": 1990,
      "summary": {
        "text": "Acknowledges those who coordinated and contributed to the 2022 guidelines on tuberculosis in children and adolescents, led by the WHO Global Tuberculosis Programme. It lists the Guideline Development Group members with their institutions, along with reviewers, observers and the systematic review teams. Funding for the update came from Unitaid and USAID.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "stellenbosch university",
          "heading": false
        },
        {
          "term": "university college",
          "heading": false
        },
        {
          "term": "united kingdom",
          "heading": false
        },
        {
          "term": "baylor college",
          "heading": false
        },
        {
          "term": "brown university",
          "heading": false
        },
        {
          "term": "mcgill university",
          "heading": false
        },
        {
          "term": "rhode island",
          "heading": false
        },
        {
          "term": "makerere university",
          "heading": false
        }
      ],
      "extract": "Acknowledgements The production and writing of the WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents, 2022 was coordinated by Sabine Verkuijl, Annemieke Brands, Kerri Viney and Tiziana Masini, under the guidance of Farai Mavhunga, head of the TB Vulnerable Populations, Communities and Comorbidities unit and the overall direction of Tereza Kasaeva, Director",
      "extractCut": true
    },
    {
      "id": "sec-001-abbreviations",
      "number": null,
      "title": "Abbreviations",
      "level": 1,
      "pageStart": 11,
      "pageEnd": 13,
      "labelStart": "ix",
      "labelEnd": "xi",
      "words": 250,
      "summary": {
        "text": "The list of abbreviations used in the guidelines on tuberculosis in children and adolescents.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "line-probe assay",
          "heading": false
        },
        {
          "term": "drug-resistant tuberculosis",
          "heading": false
        },
        {
          "term": "stool processing",
          "heading": false
        },
        {
          "term": "abbreviations",
          "heading": true
        },
        {
          "term": "chest",
          "heading": false
        },
        {
          "term": "immunodeficiency",
          "heading": false
        },
        {
          "term": "isoniazid",
          "heading": false
        },
        {
          "term": "amplification",
          "heading": false
        }
      ],
      "extract": "Abbreviations AIDS acquired immunodeficiency syndrome ANC antenatal care ART antiretroviral treatment BCG bacille Calmette-Guérin C(A)LHIV children (and adolescents) living with HIV infection CHW community health worker CXR chest X-ray or chest radiography DR-TB drug-resistant tuberculosis DS-TB drug-susceptible tuberculosis DST drug susceptibility testing DTG dolutegravir E ethambutol EPTB extrapulmonary TB Eto",
      "extractCut": true
    },
    {
      "id": "sec-002-definitions",
      "number": null,
      "title": "Definitions",
      "level": 1,
      "pageStart": 13,
      "pageEnd": 19,
      "labelStart": "xi",
      "labelEnd": "xvii",
      "words": 2506,
      "summary": {
        "text": "Defines terms used in the guidelines, such as active case-finding, adherence, advanced HIV disease, adverse events and age groups from infant to adolescent. Many further definitions cover diagnostic, treatment, drug-resistance and outcome terms. Definitions apply to this document and may differ elsewhere. The section ends with references, including WHO consultations on outcome definitions.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberculosis strains",
          "heading": false
        },
        {
          "term": "mdr rr-tb",
          "heading": false
        },
        {
          "term": "strains resistant",
          "heading": false
        },
        {
          "term": "tuberculosis disease",
          "heading": false
        },
        {
          "term": "children aged",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "tuberculosis preventive",
          "heading": false
        },
        {
          "term": "aged years",
          "heading": false
        }
      ],
      "extract": "Unless otherwise specified, the terms defined here apply as used in this document. They may have different meanings in other contexts. Active (tuberculosis) case-finding: Provider-initiated screening and testing in communities by mobile teams, often using mobile X-ray and rapid molecular tests. The term is sometimes used synonymously with “systematic screening”. Adherence: Extent to which a person’s behaviour (e.g.",
      "extractCut": true
    },
    {
      "id": "sec-003-executive-summary",
      "number": null,
      "title": "Executive summary",
      "level": 1,
      "pageStart": 19,
      "pageEnd": 25,
      "labelStart": "xvii",
      "labelEnd": "1",
      "words": 2067,
      "summary": {
        "text": "Summarises the 2022 guidelines, noting that about 1.1 million children fall ill with tuberculosis each year and fewer than half are notified, with low uptake of preventive treatment among young contacts. It sets out global targets, the rationale for updating the 2014 guidance, the objectives and the target audience. It lists the eight new recommendations, including Xpert Ultra as the first test on several specimen types, treatment decision algorithms, a 4-month regimen for non-severe tuberculosis, bedaquiline and delamanid for young children with drug-resistant tuberculosis and a 6-month regimen for tuberculous meningitis. A table of consolidated existing recommendations follows, covering areas such as HIV care, nutrition and contact investigation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mdr rr-tb",
          "heading": false
        },
        {
          "term": "rr-tb aged",
          "heading": false
        },
        {
          "term": "million children",
          "heading": false
        },
        {
          "term": "conditional recommendation",
          "heading": false
        },
        {
          "term": "longer regimens",
          "heading": false
        },
        {
          "term": "treatment regimen",
          "heading": false
        },
        {
          "term": "bedaquiline-containing regimen",
          "heading": false
        },
        {
          "term": "preventive treatment",
          "heading": false
        }
      ],
      "extract": "Introduction Children and young adolescents (aged below 15 years) represent about 11% of all people with tuberculosis (TB) globally. This means that 1.1 million children become ill with TB every year, almost half of them below five years of age. National TB programmes (NTPs) only notify less than half of these children, meaning that there is a large case detection gap (1). The reasons for this gap include challenges",
      "extractCut": true
    },
    {
      "id": "sec-004-1-introduction",
      "number": "1",
      "title": "Introduction",
      "level": 1,
      "pageStart": 25,
      "pageEnd": 25,
      "labelStart": "1",
      "labelEnd": "1",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-005-11-background",
      "number": "1.1",
      "title": "Background",
      "level": 2,
      "pageStart": 25,
      "pageEnd": 26,
      "labelStart": "1",
      "labelEnd": "2",
      "words": 684,
      "summary": {
        "text": "Gives the background to the guidelines, noting the burden of tuberculosis in children and young adolescents, the case detection gap due to diagnostic difficulties and the 24% fall in child notifications in 2020 linked to COVID-19. It also mentions low preventive treatment coverage and explains that this update brings all relevant recommendations together in one guideline.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "million children",
          "heading": false
        },
        {
          "term": "million people",
          "heading": false
        },
        {
          "term": "young children",
          "heading": false
        },
        {
          "term": "young adolescents",
          "heading": false
        },
        {
          "term": "child contacts",
          "heading": false
        },
        {
          "term": "five years",
          "heading": false
        },
        {
          "term": "accessed january",
          "heading": false
        },
        {
          "term": "below five",
          "heading": false
        }
      ],
      "extract": "Children and young adolescents (aged below 15 years) represent about 11% of all people with TB globally. This means that close to 1.1 million children become ill with TB every year, almost half of them below five years of age. National TB programmes (NTPs) only notify less than half of these children, meaning that there is a large case detection gap (1). The reasons for this gap include challenges with specimen",
      "extractCut": true
    },
    {
      "id": "sec-006-12-rationale-for-the-development-of-the-2022-con",
      "number": "1.2",
      "title": "Rationale for the development of the 2022 consolidated guidelines",
      "level": 2,
      "pageStart": 26,
      "pageEnd": 26,
      "labelStart": "2",
      "labelEnd": "2",
      "words": 139,
      "summary": {
        "text": "Explains that new research since the 2014 WHO guidance on childhood tuberculosis prompted a review and update, with new and existing recommendations brought together in one consolidated guideline.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "consolidated",
          "heading": true
        },
        {
          "term": "guidelines",
          "heading": true
        },
        {
          "term": "pharmacodynamic",
          "heading": false
        },
        {
          "term": "relevance",
          "heading": false
        }
      ],
      "extract": "consolidated guidelines Since the publication of the WHO Guidance for national tuberculosis programmes on the management of tuberculosis in children (second edition) (2014) (8), there have been numerous studies, including reviews, randomized controlled trials, observational studies, pharmacokinetic (PK) and pharmacodynamic studies, qualitative research and cost-effectiveness research, which have evaluated the impact",
      "extractCut": true
    },
    {
      "id": "sec-007-13-objectives-of-the-2022-consolidated-guideline",
      "number": "1.3",
      "title": "Objectives of the 2022 consolidated guidelines",
      "level": 2,
      "pageStart": 26,
      "pageEnd": 26,
      "labelStart": "2",
      "labelEnd": "2",
      "words": 119,
      "summary": {
        "text": "States the guidelines' objectives: to give evidence-based recommendations across the cascade of care for children and adolescents and to help cut tuberculosis illness and death in line with global targets.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "adolescents",
          "heading": false
        },
        {
          "term": "children",
          "heading": false
        },
        {
          "term": "consolidated",
          "heading": true
        }
      ],
      "extract": "The objectives of the 2022 consolidated guidelines on the management of TB in children and adolescents are to: 1. provide policy-makers and implementing partners with evidence-based recommendations on the entire cascade of care for children and adolescents to support the implementation of activities to prevent TB among children and adolescents at risk, and to improve TB case detection and treatment outcomes in",
      "extractCut": true
    },
    {
      "id": "sec-008-14-target-audience",
      "number": "1.4",
      "title": "Target audience",
      "level": 2,
      "pageStart": 26,
      "pageEnd": 26,
      "labelStart": "2",
      "labelEnd": "2",
      "words": 73,
      "summary": {
        "text": "Identifies the target audience as tuberculosis, primary care, maternal and child health and AIDS programmes, clinicians, and civil society and implementing partners.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "target",
          "heading": true
        },
        {
          "term": "audience",
          "heading": true
        },
        {
          "term": "paediatricians",
          "heading": false
        }
      ],
      "extract": "The target audience for these consolidated guidelines consists primarily of NTPs, primary health care (PHC) programmes, maternal and child health programmes, national AIDS programmes (or their equivalents in health ministries) and other health policy-makers. They also target generalist and specialist paediatricians, clinicians and health practitioners working on TB, HIV and/or infectious diseases in public and",
      "extractCut": true
    },
    {
      "id": "sec-009-15-who-recommendations-relevant-to-the-managemen",
      "number": "1.5",
      "title": "WHO recommendations relevant to the management of TB in children and adolescents",
      "level": 2,
      "pageStart": 26,
      "pageEnd": 27,
      "labelStart": "2",
      "labelEnd": "3",
      "words": 340,
      "summary": {
        "text": "Explains that the 2022 WHO consolidated guidelines on managing TB in children and adolescents combine new evidence-based recommendations, relevant recommendations from other WHO TB guidelines since 2014 and some unchanged 2014 recommendations. It notes that source wording and age definitions are kept and points users to the WHO TB Knowledge Sharing Platform and web annexes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "adolescents",
          "heading": true
        },
        {
          "term": "recommendations",
          "heading": true
        },
        {
          "term": "children",
          "heading": true
        },
        {
          "term": "consolidated guidelines",
          "heading": false
        },
        {
          "term": "guideline update",
          "heading": false
        },
        {
          "term": "guidelines issued",
          "heading": false
        },
        {
          "term": "recommendations based",
          "heading": false
        },
        {
          "term": "source guidelines",
          "heading": false
        }
      ],
      "extract": "management of TB in children and adolescents The 2022 consolidated guidelines represent a significant update compared to the previous guidelines issued in 2014. They include: (i) new recommendations based on the review of newly available evidence related to the Population, Intervention, Comparator and Outcomes (PICO) questions that were developed for this guideline update; (ii) recommendations with relevance to",
      "extractCut": true
    },
    {
      "id": "sec-010-16-scope-of-the-guideline-update",
      "number": "1.6",
      "title": "Scope of the guideline update",
      "level": 2,
      "pageStart": 27,
      "pageEnd": 30,
      "labelStart": "3",
      "labelEnd": "6",
      "words": 1319,
      "summary": {
        "text": "Sets the scope of the guideline update, defining children as under 10 and adolescents as 10–19 years, and uses the cascade of care from TB exposure to treatment outcome as its analytical framework, shown in a figure. It lists the PICO questions addressed, on diagnosis, treatment and models of care such as decentralized and family-centred integrated services. Two background questions concern the socioeconomic impact of TB on families and how best to engage adolescents in care.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "children aged",
          "heading": false
        },
        {
          "term": "pico question",
          "heading": false
        },
        {
          "term": "adolescents exposed",
          "heading": false
        },
        {
          "term": "aged below",
          "heading": false
        },
        {
          "term": "regimens conforming",
          "heading": false
        },
        {
          "term": "eligible children",
          "heading": false
        },
        {
          "term": "mdr rr-tb",
          "heading": false
        },
        {
          "term": "treatment regimen",
          "heading": false
        }
      ],
      "extract": "The population of interest in these guidelines is children and adolescents, defined as: • A child is a person under 10 years of age. • An adolescent is a person 10–19 years of age (inclusive). The pathway of TB infection and disease in an individual child or adolescent, and the interface with and retention across sequential stages of care (termed the ‘cascade of care’) was used as the analytic framework during the",
      "extractCut": true
    },
    {
      "id": "sec-011-17-publication-dissemination-evaluation-and-expi",
      "number": "1.7",
      "title": "Publication, dissemination, evaluation and expiry",
      "level": 2,
      "pageStart": 30,
      "pageEnd": 30,
      "labelStart": "6",
      "labelEnd": "6",
      "words": 253,
      "summary": {
        "text": "Describes how the guidelines will be published on the WHO TB Knowledge Sharing Platform and disseminated through webinars, training and technical support, and lists the age-disaggregated indicators that will be monitored. It states that the recommendations will be reviewed within five years, and the interim recommendation on treatment decision algorithms within two years.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "young adolescents",
          "heading": false
        },
        {
          "term": "consolidated guidelines",
          "heading": false
        },
        {
          "term": "years",
          "heading": false
        },
        {
          "term": "children",
          "heading": false
        },
        {
          "term": "dissemination",
          "heading": true
        },
        {
          "term": "contacts",
          "heading": false
        },
        {
          "term": "materials",
          "heading": false
        }
      ],
      "extract": "The electronic version of the consolidated guidelines on the management of TB in children and adolescents will form part of the WHO TB KSP, which features the following components for each TB module: (i) consolidated guidelines, (ii) operational handbooks with implementation guidance; as well as (iii) a catalogue of WHO e-learning materials. Further dissemination strategies include global, regional and country",
      "extractCut": true
    },
    {
      "id": "sec-012-18-document-structure",
      "number": "1.8",
      "title": "Document structure",
      "level": 2,
      "pageStart": 30,
      "pageEnd": 33,
      "labelStart": "6",
      "labelEnd": "9",
      "words": 613,
      "summary": {
        "text": "Outlines the structure of the 2022 guidelines chapter by chapter, from the introduction through screening and contact investigation, prevention, diagnosis and treatment to care of children with TB and HIV or malnutrition. It notes which chapters contain new recommendations and that the final chapter sets out research priorities.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mdr rr-tb",
          "heading": false
        },
        {
          "term": "chapter focuses",
          "heading": false
        },
        {
          "term": "treat mdr",
          "heading": false
        },
        {
          "term": "existing recommendations",
          "heading": false
        },
        {
          "term": "longer regimens",
          "heading": false
        },
        {
          "term": "decentralized care",
          "heading": false
        },
        {
          "term": "gdg meeting",
          "heading": false
        },
        {
          "term": "contact investigation",
          "heading": false
        }
      ],
      "extract": "A summary of the structure of the guidelines including a brief description of the contents is provided in Box 1. Î Chapter 1 is the introduction and provides background information, an overview of the scope (including PICO and background questions), the rationale, objectives and target audience for the guidelines. Î Chapter 2 includes WHO recommendations on TB screening and contact investigation that are relevant to",
      "extractCut": true
    },
    {
      "id": "sec-013-2-tb-screening-and-contact-investigation",
      "number": "2",
      "title": "TB screening and contact investigation",
      "level": 1,
      "pageStart": 33,
      "pageEnd": 35,
      "labelStart": "9",
      "labelEnd": "11",
      "words": 759,
      "summary": {
        "text": "Opens chapter 2 by consolidating existing WHO recommendations on TB screening and contact investigation relevant to children and adolescents. Table 3 lists recommendations such as systematically screening household contacts and people living with HIV, and HIV counselling and testing of contacts depending on HIV prevalence.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "contact investigation",
          "heading": true
        },
        {
          "term": "conditional recommendation",
          "heading": false
        },
        {
          "term": "strong recommendation",
          "heading": false
        },
        {
          "term": "screening",
          "heading": true
        },
        {
          "term": "moderate certainty",
          "heading": false
        },
        {
          "term": "symptom screen",
          "heading": false
        },
        {
          "term": "household contacts",
          "heading": false
        },
        {
          "term": "close contacts",
          "heading": false
        }
      ],
      "extract": "2. TB screening and contact investigation This chapter includes current WHO recommendations that apply to children and adolescents on TB screening and contact investigation. They have been consolidated from current WHO guidelines on systematic screening for TB disease and contact investigation, namely the WHO consolidated guidelines on tuberculosis. Module 2: screening – systematic screening for tuberculosis disease",
      "extractCut": true
    },
    {
      "id": "sec-014-3-prevention-of-tb",
      "number": "3",
      "title": "Prevention of TB",
      "level": 1,
      "pageStart": 35,
      "pageEnd": 41,
      "labelStart": "11",
      "labelEnd": "17",
      "words": 2135,
      "summary": {
        "text": "Consolidates WHO recommendations on TB prevention relevant to children and adolescents, drawn from guidelines on infection prevention and control, the BCG vaccine position paper and guidelines on TB preventive treatment. Table 4 lists measures such as triage and respiratory isolation of people with TB symptoms, BCG vaccination, testing for TB infection and preventive treatment regimens. Recommendations on preventive therapy for people living with HIV, including 36 months of isoniazid in high-transmission settings, close the section.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "leprosy neonates",
          "heading": false
        },
        {
          "term": "conditional recommendation",
          "heading": false
        },
        {
          "term": "bcg vaccination",
          "heading": false
        },
        {
          "term": "strong recommendation",
          "heading": false
        },
        {
          "term": "tuberculosis preventive",
          "heading": false
        },
        {
          "term": "preventive treatment",
          "heading": false
        },
        {
          "term": "bcg vaccine",
          "heading": false
        },
        {
          "term": "moderate certainty",
          "heading": false
        }
      ],
      "extract": "This chapter includes current WHO recommendations that apply to children and adolescents on TB prevention. They have been consolidated from current WHO guidelines on TB infection, prevention and control, a BCG position paper and guidelines on TPT, namely the WHO guidelines on tuberculosis infection prevention and control, 2019 update (12), the BCG vaccines: WHO position paper (published in the Weekly Epidemiological",
      "extractCut": true
    },
    {
      "id": "sec-015-4-diagnostic-approaches-for-tb-in-children-and-a",
      "number": "4",
      "title": "Diagnostic approaches for TB in children and adolescents",
      "level": 1,
      "pageStart": 41,
      "pageEnd": 42,
      "labelStart": "17",
      "labelEnd": "18",
      "words": 592,
      "summary": {
        "text": "Describes the gap in TB diagnosis among children, with only about a third of an estimated 1.1 million cases notified in 2020 and most deaths occurring in under-fives who never received treatment. It explains causes such as paucibacillary disease, lack of a sensitive point-of-care test, sampling difficulties and limited primary care capacity, and notes a 2021 expert consultation advising that intrathoracic lymph node TB be classified as pulmonary TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "children",
          "heading": true
        },
        {
          "term": "among children",
          "heading": false
        },
        {
          "term": "bacteriological tests",
          "heading": false
        },
        {
          "term": "children below",
          "heading": false
        },
        {
          "term": "gastric aspirate",
          "heading": false
        },
        {
          "term": "serodiagnostic tests",
          "heading": false
        },
        {
          "term": "commercial serodiagnostic",
          "heading": false
        },
        {
          "term": "adolescents",
          "heading": true
        }
      ],
      "extract": "in children and adolescents Of the estimated 1.1 million children who developed TB annually, only 399 000 (36.5%) were notified to NTPs in 2020. Under-notification is worst among children below 5 years of age, with only 27.5% of children with TB being notified (1). These ‘missing’ children are not diagnosed and/or not reported. TB-related mortality among children below 15 years of age was estimated at 226 000 for",
      "extractCut": true
    },
    {
      "id": "sec-016-41-the-use-of-the-xpert-mtbrif-ultra-assay-in-ga",
      "number": "4.1",
      "title": "The use of the Xpert MTB/RIF Ultra assay in gastric aspirate and stool specimens for the diagnosis of pulmonary TB and rifampicin resistance",
      "level": 2,
      "pageStart": 42,
      "pageEnd": 46,
      "labelStart": "18",
      "labelEnd": "22",
      "words": 2376,
      "summary": {
        "text": "Recommends Xpert MTB/RIF Ultra as the initial test for pulmonary TB and rifampicin resistance in children using sputum, nasopharyngeal aspirate, gastric aspirate or stool, instead of smear microscopy, culture and phenotypic drug susceptibility testing. It sets out the justification and evidence, noting the limited sensitivity of the earlier Xpert MTB/RIF assay among children and people with HIV. Implementation considerations cover acceptability and feasibility of specimen collection, and monitoring advice covers laboratory registers and reporting notifications by five-year age group.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "gastric aspirate",
          "heading": true
        },
        {
          "term": "gastric specimens",
          "heading": true
        },
        {
          "term": "stool specimens",
          "heading": true
        },
        {
          "term": "xpert ultra",
          "heading": true
        },
        {
          "term": "ultra assay",
          "heading": true
        },
        {
          "term": "xpert mtb",
          "heading": true
        },
        {
          "term": "rifampicin resistance",
          "heading": true
        },
        {
          "term": "stool processing",
          "heading": false
        }
      ],
      "extract": "in gastric aspirate and stool specimens for the diagnosis of pulmonary TB and rifampicin resistance Recommendation: In children with signs and symptoms of pulmonary TB, Xpert Ultra should be used as the initial diagnostic test for TB and detection of rifampicin resistance on sputum, nasopharyngeal aspirate, gastric aspirate or stool, rather than smear microscopy/culture and phenotypic drug susceptibility testing",
      "extractCut": true
    },
    {
      "id": "sec-017-42-treatment-decision-algorithms-for-the-diagnos",
      "number": "4.2",
      "title": "Treatment decision algorithms for the diagnosis of pulmonary TB in children aged below 10 years of age",
      "level": 2,
      "pageStart": 46,
      "pageEnd": 50,
      "labelStart": "22",
      "labelEnd": "26",
      "words": 2302,
      "summary": {
        "text": "Gives an interim conditional recommendation that integrated treatment decision algorithms may be used to diagnose pulmonary TB in children under 10 with presumptive TB, while still seeking bacteriological confirmation where possible. It explains that new algorithms are detailed in the operational handbook and that the recommendation will be reviewed after 24 months. The section covers the evidence, the need to suspect drug-resistant TB where relevant, and monitoring of treatment response and outcomes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "decision algorithms",
          "heading": true
        },
        {
          "term": "children aged",
          "heading": true
        },
        {
          "term": "treatment decision",
          "heading": true
        },
        {
          "term": "aged below",
          "heading": true
        },
        {
          "term": "ntlp algorithm",
          "heading": false
        },
        {
          "term": "evidence-based algorithms",
          "heading": false
        },
        {
          "term": "treatment-decision algorithms",
          "heading": false
        },
        {
          "term": "below years",
          "heading": true
        }
      ],
      "extract": "of pulmonary TB in children aged below 10 years of age Interim recommendation In children with presumptive pulmonary TB attending health care facilities, integrated treatment decision algorithms may be used to diagnose pulmonary TB. (Conditional recommendation, very low certainty of evidence). Remarks • Presumptive TB refers to a person who presents with symptoms and/or signs suggestive of TB.24 • Bacteriological",
      "extractCut": true
    },
    {
      "id": "sec-018-43-consolidated-recommendations-on-tb-diagnostic",
      "number": "4.3",
      "title": "Consolidated recommendations on TB diagnostics and diagnostic approaches relevant to children and adolescents",
      "level": 2,
      "pageStart": 50,
      "pageEnd": 55,
      "labelStart": "26",
      "labelEnd": "31",
      "words": 2154,
      "summary": {
        "text": "Table 5 consolidates WHO recommendations on TB diagnostics relevant to children and adolescents, including Xpert MTB/RIF and Ultra as initial tests on various specimen types and molecular tests for detecting drug resistance. It notes that adults in the source guidelines include adolescents aged 15 and over, and states that commercial serodiagnostic tests should not be used for children. The page ends with the opening of chapter 5 on treatment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "conditional recommendation",
          "heading": false
        },
        {
          "term": "moderate certainty",
          "heading": false
        },
        {
          "term": "certainty evidence",
          "heading": false
        },
        {
          "term": "phenotypic dst",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "strong recommendation",
          "heading": false
        },
        {
          "term": "culture-based phenotypic",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        }
      ],
      "extract": "diagnostics and diagnostic approaches relevant to children and adolescents Table 5: WHO recommendations on diagnostic approaches relevant to children and adolescents WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection, 2021 update (16) Recommendations on Xpert MTB/RIF and Xpert Ultra as initial tests in adults and children with signs and symptoms of",
      "extractCut": true
    },
    {
      "id": "sec-019-5-treatment-of-tb-disease-in-children-and-adoles",
      "number": "5",
      "title": "Treatment of TB disease in children and adolescents",
      "level": 1,
      "pageStart": 55,
      "pageEnd": 56,
      "labelStart": "31",
      "labelEnd": "32",
      "words": 232,
      "summary": {
        "text": "Introduces the treatment chapter, listing four new recommendations: a four-month regimen for non-severe drug-susceptible TB, a six-month intensive regimen for TB meningitis, and bedaquiline and delamanid for children of all ages with MDR/RR-TB. It notes the source guidelines from which other treatment recommendations are consolidated.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "children",
          "heading": true
        },
        {
          "term": "mdr rr-tb",
          "heading": false
        },
        {
          "term": "tuberculosis treatment",
          "heading": false
        },
        {
          "term": "treat mdr",
          "heading": false
        },
        {
          "term": "consolidated guidelines",
          "heading": false
        },
        {
          "term": "adolescents",
          "heading": true
        },
        {
          "term": "longer regimens",
          "heading": false
        }
      ],
      "extract": "WHO recommendations that apply to the treatment of TB in children and adolescents (section 5.4). The four new recommendations concern drug-susceptible TB (DS-TB): (i) a four-month regimen for children and adolescents below 16 years of age with non-severe drug-susceptible TB (section 5.1); (ii) a six-month intensive regimen to treat TBM composed of isoniazid, rifampicin, pyrazinamide and ethionamide (section 5.2);",
      "extractCut": true
    },
    {
      "id": "sec-020-51-treatment-shortening-in-children-and-adolesce",
      "number": "5.1",
      "title": "Treatment shortening in children and adolescents with non-severe TB",
      "level": 2,
      "pageStart": 56,
      "pageEnd": 61,
      "labelStart": "32",
      "labelEnd": "37",
      "words": 3198,
      "summary": {
        "text": "Recommends a four-month regimen for children and adolescents aged 3 months to 16 years with non-severe TB, defining non-severe disease and advising the standard six-month regimen for others. It notes ethambutol should be added in settings with high HIV or isoniazid resistance prevalence. The justification cites potential benefits of shorter treatment for costs, toxicity, drug interactions and adherence. Implementation considerations stress accurate classification of severity and follow-up for up to 12 months after treatment to detect relapse.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "non-severe",
          "heading": true
        },
        {
          "term": "shine trial",
          "heading": false
        },
        {
          "term": "shorter regimen",
          "heading": false
        },
        {
          "term": "week regimen",
          "heading": false
        },
        {
          "term": "month regimen",
          "heading": false
        },
        {
          "term": "hpmz regimen",
          "heading": false
        },
        {
          "term": "week arm",
          "heading": false
        },
        {
          "term": "month hrz",
          "heading": false
        }
      ],
      "extract": "adolescents with non-severe TB Recommendation: In children and adolescents between 3 months and 16 years of age with non-severe TB (without suspicion or evidence of MDR/RR-TB), a 4-month treatment regimen (2HRZ(E)/2HR) should be used. (Strong recommendation, moderate certainty of evidence) Remarks • Non-severe TB is defined as: Peripheral lymph node TB; intrathoracic lymph node TB without airway obstruction;",
      "extractCut": true
    },
    {
      "id": "sec-021-52-treatment-regimens-for-tb-meningitis-in-child",
      "number": "5.2",
      "title": "Treatment regimens for TB meningitis in children and adolescents",
      "level": 2,
      "pageStart": 61,
      "pageEnd": 65,
      "labelStart": "37",
      "labelEnd": "41",
      "words": 2731,
      "summary": {
        "text": "Gives a conditional recommendation that a six-month intensive regimen of isoniazid, rifampicin, pyrazinamide and ethionamide may be used as an alternative to the 12-month regimen for TB meningitis in children and adolescents without drug resistance. It notes the 12-month regimen remains an option and that the shorter regimen should not be used in those living with HIV owing to lack of data. Evidence, diagnostic considerations and monitoring of uptake and outcomes are also covered.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "treatment regimens",
          "heading": true
        },
        {
          "term": "tbm kids",
          "heading": false
        },
        {
          "term": "shorter regimen",
          "heading": false
        },
        {
          "term": "comparator regimen",
          "heading": false
        },
        {
          "term": "neurological sequelae",
          "heading": false
        },
        {
          "term": "intensive regimen",
          "heading": false
        },
        {
          "term": "treat tbm",
          "heading": false
        },
        {
          "term": "month regimen",
          "heading": false
        }
      ],
      "extract": "and adolescents Recommendation In children and adolescents with bacteriologically confirmed or clinically diagnosed TB meningitis (without suspicion or evidence of MDR/RR-TB), a 6-month intensive regimen (6HRZEto) may be used as an alternative option to the 12-month regimen (2HRZE/10HR) (Conditional recommendation, very low certainty of the evidence). Remarks • The shorter intensive regimen is suitable for children",
      "extractCut": true
    },
    {
      "id": "sec-022-53-treatment-of-multi-drug-and-rifampicin-resist",
      "number": "5.3",
      "title": "Treatment of multi-drug and rifampicin resistant TB in children",
      "level": 2,
      "pageStart": 65,
      "pageEnd": 77,
      "labelStart": "41",
      "labelEnd": "53",
      "words": 7289,
      "summary": {
        "text": "Addresses treatment of MDR/RR-TB in children, noting an estimated 25 000–32 000 cases a year but only a few thousand started on second-line treatment, with numbers falling during COVID-19. It presents the recommendation on bedaquiline for children of all ages, explaining that earlier advice applied only from age 6 because of limited pharmacokinetic and safety data in younger children. It then covers delamanid for children of all ages within longer regimens. Implementation and monitoring points include the risk of delamanid resistance, cardiac and neuropsychiatric safety monitoring, and recording treatment outcomes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mdr rr-tb",
          "heading": false
        },
        {
          "term": "all-oral bedaquiline-containing",
          "heading": false
        },
        {
          "term": "all-oral regimens",
          "heading": false
        },
        {
          "term": "bedaquiline tablets",
          "heading": false
        },
        {
          "term": "shorter all-oral",
          "heading": false
        },
        {
          "term": "rr-tb aged",
          "heading": false
        },
        {
          "term": "administering delamanid",
          "heading": false
        },
        {
          "term": "bedaquiline containing",
          "heading": false
        }
      ],
      "extract": "TB in children Around 25 000–32 000 children are estimated to develop MDR/RR-TB every year (75–77). In 2018, 3398 children (aged below 15 years) were started on second-line treatment for MDR/RR-TB. After increasing to 5586 in 2019, due to the impact of the COVID-19 pandemic, this number dropped back to 3234 in 2020, representing only 2.5% of the total number of persons with MDR/RR-TB initiated on treatment and only",
      "extractCut": true
    },
    {
      "id": "sec-023-54-consolidated-recommendations-on-tb-treatment",
      "number": "5.4",
      "title": "Consolidated recommendations on TB treatment for children and adolescents",
      "level": 2,
      "pageStart": 77,
      "pageEnd": 81,
      "labelStart": "53",
      "labelEnd": "57",
      "words": 1365,
      "summary": {
        "text": "Reproduces, in Table 6 of WHO's consolidated guidelines on managing tuberculosis in children and adolescents (Module 5), existing WHO recommendations on TB treatment for this age group. These cover regimens for drug-susceptible pulmonary, peripheral lymph node, osteoarticular and meningeal TB, with dosing advice for young infants and the 4-month rifapentine–moxifloxacin regimen from age 12. It also lists recommendations for isoniazid-resistant and multidrug- or rifampicin-resistant TB, ending with notes on treatment monitoring by sputum testing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mdr rr-tb",
          "heading": false
        },
        {
          "term": "rr-tb patients",
          "heading": false
        },
        {
          "term": "conditional recommendation",
          "heading": false
        },
        {
          "term": "longer regimens",
          "heading": false
        },
        {
          "term": "two-drug regimen",
          "heading": false
        },
        {
          "term": "strong recommendation",
          "heading": false
        },
        {
          "term": "treatment regimen",
          "heading": false
        },
        {
          "term": "four-drug regimen",
          "heading": false
        }
      ],
      "extract": "for children and adolescents Table 6: WHO recommendations on TB treatment relevant to children and adolescents Guidance for national tuberculosis programmes on the management of tuberculosis in children. Second edition, 2014 (8) Children with pulmonary TB or tuberculous peripheral lymphadenitis who live in settings with low HIV prevalence and/or low prevalence of isoniazid resistance and children who are HIV-",
      "extractCut": true
    },
    {
      "id": "sec-024-6-models-of-tb-care-for-case-detection-and-provi",
      "number": "6",
      "title": "Models of TB care for case detection and provision of TPT in children and adolescents",
      "level": 1,
      "pageStart": 81,
      "pageEnd": 82,
      "labelStart": "57",
      "labelEnd": "58",
      "words": 673,
      "summary": {
        "text": "Introduces the chapter on models of TB care for case detection and preventive treatment in children and adolescents, noting two new recommendations and other consolidated ones on patient support. It describes how paediatric TB capacity is often centralised, primary care staff lack confidence and many chances for contact tracing and prevention are missed, which frames the questions on decentralised and family-centred care.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "case detection",
          "heading": true
        },
        {
          "term": "tpt",
          "heading": true
        },
        {
          "term": "adolescents",
          "heading": true
        },
        {
          "term": "children",
          "heading": true
        },
        {
          "term": "models",
          "heading": true
        },
        {
          "term": "integrate child",
          "heading": false
        },
        {
          "term": "care",
          "heading": true
        },
        {
          "term": "decentralized models",
          "heading": false
        }
      ],
      "extract": "detection and provision of TPT in children and adolescents This chapter contains two new recommendations and other valid WHO recommendations that apply to patient support and models of care (section 6.2). The two new recommendations, on the implementation of decentralized models of care and integrated family-centred models of care to improve both case detection and the provision of TPT, are described in full detail",
      "extractCut": true
    },
    {
      "id": "sec-025-61-decentralized-and-family-centred-integrated-m",
      "number": "6.1",
      "title": "Decentralized and family-centred, integrated models of care to deliver child and adolescent TB services",
      "level": 2,
      "pageStart": 82,
      "pageEnd": 87,
      "labelStart": "58",
      "labelEnd": "63",
      "words": 2992,
      "summary": {
        "text": "Sets out two new conditional recommendations, based on very low certainty evidence, that decentralised and family-centred, integrated models of care are options for delivering TB services to children and adolescents with TB symptoms or exposure. Remarks clarify that decentralisation strengthens services at lower levels rather than replacing specialist care, and should target areas with poor access or high prevalence. The section then presents the justification and evidence and implementation considerations, including differentiated service delivery. It ends with monitoring and evaluation advice on planning, registers, sex-disaggregated data and service quality.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "family-centred care",
          "heading": true
        },
        {
          "term": "integrated services",
          "heading": true
        },
        {
          "term": "decentralized",
          "heading": true
        },
        {
          "term": "adolescent",
          "heading": true
        },
        {
          "term": "child",
          "heading": true
        },
        {
          "term": "practice decentralization",
          "heading": false
        },
        {
          "term": "decentralized approaches",
          "heading": false
        },
        {
          "term": "favours decentralized",
          "heading": false
        }
      ],
      "extract": "models of care to deliver child and adolescent TB services Recommendations: In TB high burden settings, decentralized models of care may be used to deliver TB services to children and adolescents with signs and symptoms of TB and/or those exposed to TB (conditional recommendation, very low certainty evidence). Family-centred, integrated models of care to deliver TB services may be used in children and adolescents",
      "extractCut": true
    },
    {
      "id": "sec-026-62-consolidated-recommendations-on-models-of-tb",
      "number": "6.2",
      "title": "Consolidated recommendations on models of TB care relevant to children and adolescents",
      "level": 2,
      "pageStart": 87,
      "pageEnd": 89,
      "labelStart": "63",
      "labelEnd": "65",
      "words": 574,
      "summary": {
        "text": "Table 7 lists WHO recommendations on care and support during TB treatment that apply to children and adolescents, including health education, adherence interventions such as tracers, material and psychological support, and community- or home-based and video-supported treatment options. Footnotes explain what each type of support involves.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "conditional recommendation",
          "heading": false
        },
        {
          "term": "unsupported treatment",
          "heading": false
        },
        {
          "term": "care relevant",
          "heading": true
        },
        {
          "term": "treatment adherence",
          "heading": false
        },
        {
          "term": "treatment support",
          "heading": false
        },
        {
          "term": "moderate certainty",
          "heading": false
        },
        {
          "term": "home-based treatment",
          "heading": false
        },
        {
          "term": "psychological support",
          "heading": false
        }
      ],
      "extract": "care relevant to children and adolescents Table 7: WHO recommendations on models of TB care relevant to children and adolescents WHO consolidated guidelines on tuberculosis. Module 4: treatment – care and support during tuberculosis treatment (100) Health education and counselling on the disease and treatment adherence should be provided to patients on TB treatment. (Strong recommendation, moderate certainty in the",
      "extractCut": true
    },
    {
      "id": "sec-027-7-special-situations",
      "number": "7",
      "title": "Special situations",
      "level": 1,
      "pageStart": 89,
      "pageEnd": 93,
      "labelStart": "65",
      "labelEnd": "69",
      "words": 1480,
      "summary": {
        "text": "Opens the chapter on special situations, covering WHO recommendations for TB in children and adolescents with HIV or malnutrition and feeding of infants of mothers with TB. Table 8 gathers recommendations on HIV testing, co-trimoxazole prophylaxis, antiretroviral therapy eligibility and timing, and TB/HIV care. It also includes nutritional recommendations, such as managing severe acute malnutrition, and ends with a note on pyridoxine with isoniazid.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "moderate undernutrition",
          "heading": false
        },
        {
          "term": "strong recommendation",
          "heading": false
        },
        {
          "term": "conditional recommendation",
          "heading": false
        },
        {
          "term": "moderate certainty",
          "heading": false
        },
        {
          "term": "certainty evidence",
          "heading": false
        },
        {
          "term": "special situations",
          "heading": true
        },
        {
          "term": "acute malnutrition",
          "heading": false
        },
        {
          "term": "fortified supplementary",
          "heading": false
        }
      ],
      "extract": "7. Special situations This chapter includes valid WHO recommendations that apply to children and adolescents in special situations such as for the management of TB in the context of HIV infection or malnutrition and optimal feeding of infants of mothers infected with TB. The recommendations have been consolidated from several current WHO guidelines on TB/HIV coinfection and nutrition, namely the WHO policy on",
      "extractCut": true
    },
    {
      "id": "sec-028-8-research-priorities",
      "number": "8",
      "title": "Research priorities",
      "level": 1,
      "pageStart": 93,
      "pageEnd": 97,
      "labelStart": "69",
      "labelEnd": "73",
      "words": 1364,
      "summary": {
        "text": "Lists research gaps identified by the guideline development group, grouped by topic such as TB screening, diagnostic approaches and treatment decision algorithms. The priorities call for studies on screening tools for different age groups, validation and implementation of diagnostic algorithms, and research on community perceptions and the quality of TB diagnosis in children.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "research priorities",
          "heading": true
        },
        {
          "term": "treatment regimens",
          "heading": false
        },
        {
          "term": "non-severe drug-susceptible",
          "heading": false
        },
        {
          "term": "studies exploring",
          "heading": false
        },
        {
          "term": "qualitative research",
          "heading": false
        },
        {
          "term": "among children",
          "heading": false
        },
        {
          "term": "mdr rr-tb",
          "heading": false
        },
        {
          "term": "children related",
          "heading": false
        }
      ],
      "extract": "8. Research priorities This chapter includes research gaps or priorities that were identified by the GDG members while considering the evidence related to each of the PICO questions. Addressing the identified research gaps has the potential to inform the development of future research questions that can improve TB prevention and care. This list of research priorities is not exhaustive; but it complements the",
      "extractCut": true
    },
    {
      "id": "sec-029-9-references",
      "number": "9",
      "title": "References",
      "level": 1,
      "pageStart": 97,
      "pageEnd": 105,
      "labelStart": "73",
      "labelEnd": "81",
      "words": 3753,
      "summary": {
        "text": "The reference list for the guideline (127 items), citing mainly WHO TB reports and guidelines and studies on childhood tuberculosis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "accessed december",
          "heading": false
        },
        {
          "term": "infect dis",
          "heading": false
        },
        {
          "term": "accessed february",
          "heading": false
        },
        {
          "term": "lung dis",
          "heading": false
        },
        {
          "term": "tuberc lung",
          "heading": false
        },
        {
          "term": "pediatr infect",
          "heading": false
        },
        {
          "term": "clin infect",
          "heading": false
        },
        {
          "term": "childhood tuberculosis",
          "heading": false
        }
      ],
      "extract": "1. Global tuberculosis report 2021. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/ handle/10665/346387, accessed 1 December 2021). 2. Marais B. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis. 2004;8(4):392-402. 3. Martinez L, Cords O, Horsburgh CR, Andrews JR, Pediatric TB Contact Studies",
      "extractCut": true
    },
    {
      "id": "sec-030-annex-1-who-recommendations-incorporated-in-the",
      "number": null,
      "title": "Annex 1. WHO recommendations incorporated in the guidelines on the management of TB in children and adolescents",
      "level": 1,
      "pageStart": 105,
      "pageEnd": 107,
      "labelStart": "81",
      "labelEnd": "83",
      "words": 274,
      "summary": {
        "text": "Annex 1 lists the WHO guidelines and position papers whose recommendations are incorporated into this module, covering screening, contact investigation, infection control, BCG, preventive treatment, diagnosis, treatment, HIV and nutrition.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberculosis treatment",
          "heading": false
        },
        {
          "term": "consolidated guidelines",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        },
        {
          "term": "children",
          "heading": true
        },
        {
          "term": "geneva",
          "heading": false
        },
        {
          "term": "module",
          "heading": false
        },
        {
          "term": "management",
          "heading": true
        }
      ],
      "extract": "Annex 1. WHO recommendations incorporated in the guidelines on the management of TB in children and adolescents In order of presentation: WHO consolidated guidelines on tuberculosis. Module 2: screening – systematic screening for tuberculosis disease. Geneva: World Health Organization; 2021. Recommendations for investigating contacts of persons with infectious tuberculosis in low- and middle-income countries.",
      "extractCut": true
    },
    {
      "id": "sec-031-annex-2-supplementary-table",
      "number": null,
      "title": "Annex 2. Supplementary table",
      "level": 1,
      "pageStart": 107,
      "pageEnd": 107,
      "labelStart": "83",
      "labelEnd": "83",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-032-summary-of-changes-to-recommendations-as-include",
      "number": null,
      "title": "Summary of changes to recommendations as included in the second edition of the Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2014",
      "level": 2,
      "pageStart": 107,
      "pageEnd": 128,
      "labelStart": "83",
      "labelEnd": "104",
      "words": 6183,
      "summary": {
        "text": "A long annex table comparing each recommendation in WHO's 2014 guidance on managing TB in children with its current status in this module. For each item it gives the original wording and source, whether it was updated, kept, copied to the operational handbook or replaced, and the new wording. Topics include Xpert MTB/RIF and Ultra diagnostic testing, treatment regimens, preventive therapy, HIV and reporting age bands, which change to 0–4, 5–9, 10–14 and 15–19 years. It also lists the new interim recommendation on treatment decision algorithms and ends with WHO Global TB Programme contact details.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberculosis programmes",
          "heading": true
        },
        {
          "term": "national tuberculosis",
          "heading": true
        },
        {
          "term": "conditional recommendation",
          "heading": false
        },
        {
          "term": "strong recommendation",
          "heading": false
        },
        {
          "term": "two-drug regimen",
          "heading": false
        },
        {
          "term": "updated recommendation",
          "heading": false
        },
        {
          "term": "children",
          "heading": true
        },
        {
          "term": "investigating contacts",
          "heading": false
        }
      ],
      "extract": "included in the second edition of the Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2014 84 WHO consolidated guidelines on tuberculosis, Module 5: Management of tuberculosis in children and adolescents No. Recommendation in Guidance for national tuberculosis programmes on the management of tuberculosis in children (second edition) 2014, and source guideline Status46",
      "extractCut": true
    }
  ],
  "checks": {
    "tocAlignment": {
      "listed_not_found": {
        "count": 0,
        "items": []
      },
      "found_not_listed": {
        "count": 0,
        "items": []
      },
      "page_mismatch": {
        "count": 0,
        "items": []
      }
    },
    "figureSequenceGaps": [],
    "pageLabelConflicts": {
      "count": 0,
      "items": []
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "children years",
      "heading": true
    },
    {
      "term": "children aged",
      "heading": true
    },
    {
      "term": "tuberculosis treatment",
      "heading": false
    },
    {
      "term": "adolescents years",
      "heading": false
    },
    {
      "term": "children living",
      "heading": false
    },
    {
      "term": "children below",
      "heading": true
    },
    {
      "term": "children treated",
      "heading": false
    },
    {
      "term": "among children",
      "heading": false
    },
    {
      "term": "young children",
      "heading": false
    },
    {
      "term": "treatment regimen",
      "heading": false
    },
    {
      "term": "rr-tb treatment",
      "heading": false
    },
    {
      "term": "tuberculosis disease",
      "heading": false
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": "a",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 2,
      "label": "b",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 3,
      "label": "i",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 4,
      "label": "ii",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 5,
      "label": "iii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 6,
      "label": "iv",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 7,
      "label": "v",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 8,
      "label": "vi",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 9,
      "label": "vii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 10,
      "label": "viii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 11,
      "label": "ix",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 12,
      "label": "x",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 13,
      "label": "xi",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 14,
      "label": "xii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 15,
      "label": "xiii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 16,
      "label": "xiv",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 17,
      "label": "xv",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 18,
      "label": "xvi",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 19,
      "label": "xvii",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 20,
      "label": "xviii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 21,
      "label": "xix",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 22,
      "label": "xx",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 23,
      "label": "xxi",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 24,
      "label": "xxii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 25,
      "label": "1",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 26,
      "label": "2",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 27,
      "label": "3",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 28,
      "label": "4",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 29,
      "label": "5",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 30,
      "label": "6",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 31,
      "label": "7",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 32,
      "label": "8",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 33,
      "label": "9",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 34,
      "label": "10",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 35,
      "label": "11",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 36,
      "label": "12",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 37,
      "label": "13",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 38,
      "label": "14",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 39,
      "label": "15",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 40,
      "label": "16",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 41,
      "label": "17",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 42,
      "label": "18",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 43,
      "label": "19",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 44,
      "label": "20",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 45,
      "label": "21",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 46,
      "label": "22",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 47,
      "label": "23",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 48,
      "label": "24",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 49,
      "label": "25",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 50,
      "label": "26",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 51,
      "label": "27",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 52,
      "label": "28",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 53,
      "label": "29",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 54,
      "label": "30",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 55,
      "label": "31",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 56,
      "label": "32",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 57,
      "label": "33",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 58,
      "label": "34",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 59,
      "label": "35",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 60,
      "label": "36",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 61,
      "label": "37",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 62,
      "label": "38",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 63,
      "label": "39",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 64,
      "label": "40",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 65,
      "label": "41",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 66,
      "label": "42",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 67,
      "label": "43",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 68,
      "label": "44",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 69,
      "label": "45",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 70,
      "label": "46",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 71,
      "label": "47",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 72,
      "label": "48",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 73,
      "label": "49",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 74,
      "label": "50",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 75,
      "label": "51",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 76,
      "label": "52",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 77,
      "label": "53",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 78,
      "label": "54",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 79,
      "label": "55",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 80,
      "label": "56",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 81,
      "label": "57",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 82,
      "label": "58",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 83,
      "label": "59",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 84,
      "label": "60",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 85,
      "label": "61",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 86,
      "label": "62",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 87,
      "label": "63",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 88,
      "label": "64",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 89,
      "label": "65",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 90,
      "label": "66",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 91,
      "label": "67",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 92,
      "label": "68",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 93,
      "label": "69",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 94,
      "label": "70",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 95,
      "label": "71",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 96,
      "label": "72",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 97,
      "label": "73",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 98,
      "label": "74",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 99,
      "label": "75",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 100,
      "label": "76",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 101,
      "label": "77",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 102,
      "label": "78",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 103,
      "label": "79",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 104,
      "label": "80",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 105,
      "label": "81",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 106,
      "label": "82",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 107,
      "label": "83",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 108,
      "label": "84",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 109,
      "label": "85",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 110,
      "label": "86",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 111,
      "label": "87",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 112,
      "label": "88",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 113,
      "label": "89",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 114,
      "label": "90",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 115,
      "label": "91",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 116,
      "label": "92",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 117,
      "label": "93",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 118,
      "label": "94",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 119,
      "label": "95",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 120,
      "label": "96",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 121,
      "label": "97",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 122,
      "label": "98",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 123,
      "label": "99",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 124,
      "label": "100",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 125,
      "label": "101",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 126,
      "label": "102",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 127,
      "label": "103",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 128,
      "label": "104",
      "source": "pdf-labels",
      "confidence": 0.7
    }
  ],
  "figures": [
    {
      "kind": "table",
      "number": "1",
      "title": "New recommendations in the WHO consolidated guidelines on tuberculosis",
      "page": 20,
      "pageLabel": "xviii",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "2",
      "title": "Recommendations in the WHO consolidated guidelines on tuberculosis. Module 5:",
      "page": 21,
      "pageLabel": "xix",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "1",
      "title": "Cascade of care in children and adolescents exposed to and with TB, with",
      "page": 28,
      "pageLabel": "4",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "2",
      "title": "The logic model used for the guidelines on the management of TB in children",
      "page": 28,
      "pageLabel": "4",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "box",
      "number": "1",
      "title": "Structure of the 2022 consolidated guidelines",
      "page": 31,
      "pageLabel": "7",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "3",
      "title": "WHO recommendations on TB screening and contact investigation relevant to",
      "page": 33,
      "pageLabel": "9",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "4",
      "title": "WHO recommendations on TB infection prevention and control, BCG",
      "page": 35,
      "pageLabel": "11",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "5",
      "title": "WHO recommendations on diagnostic approaches relevant to children and",
      "page": 50,
      "pageLabel": "26",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "6",
      "title": "WHO recommendations on TB treatment relevant to children and adolescents",
      "page": 77,
      "pageLabel": "53",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "7",
      "title": "WHO recommendations on models of TB care relevant to children and",
      "page": 87,
      "pageLabel": "63",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "8",
      "title": "WHO recommendations on TB/HIV coinfection and nutrition relevant to",
      "page": 89,
      "pageLabel": "65",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    }
  ],
  "images": [
    {
      "id": "vfig-p028",
      "file": "figures/vfig-p028.webp",
      "page": 28,
      "shows": [
        "Figure 1",
        "Figure 2"
      ],
      "narratives": {
        "en": "Page render showing the lower part of Figure 1, a cascade of TB care in children and adolescents drawn as branching paths from susceptible to exposed to infected, then to preventive treatment, diseased, did not access the health care system, or un/misdiagnosed, with PICO labels for screening in health care facilities and models of care. Below it, Figure 2 is a logic model of four linked boxes: inputs (e.g. stakeholder engagement, financial and human resources, evidence from research), activities (e.g. contact investigation, TB screening, diagnostic approaches, treatment regimens, models of care), short-term outcomes (e.g. earlier detection of DS- and DR-TB, improved treatment outcomes, increased preventive treatment coverage) and long-term outcomes (reduced TB incidence, mortality, post-TB sequelae and financial losses).",
        "ar": "عرض لصفحة يبيّن الجزء السفلي من الشكل 1، وهو سلسلة رعاية مرضى السل من الأطفال والمراهقين مرسومة في صورة مسارات متفرعة من القابلية للإصابة إلى التعرض ثم العدوى، ومنها إلى العلاج الوقائي أو المرض أو عدم الوصول إلى نظام الرعاية الصحية أو عدم التشخيص/التشخيص الخاطئ، مع تسميات PICO للتحرّي في مرافق الرعاية الصحية ونماذج الرعاية. وتحته الشكل 2، وهو نموذج منطقي من أربعة مربعات مترابطة: المدخلات (مثل إشراك أصحاب المصلحة والموارد المالية والبشرية والبيّنات البحثية)، والأنشطة (مثل تقصّي المخالطين وتحرّي السل ونُهج التشخيص ونظم العلاج ونماذج الرعاية)، والنتائج القصيرة الأجل (مثل الكشف المبكر عن السل الحساس للأدوية والسل المقاوم للأدوية، وتحسين نتائج العلاج، وزيادة التغطية بالعلاج الوقائي)، والنتائج الطويلة الأجل (خفض معدلات الإصابة بالسل والوفيات الناجمة عنه وعقابيله والخسائر المالية).",
        "zh": "页面渲染图：上部为图1的下半部分，即儿童和青少年结核病关怀级联，以分支路径表示从易感到暴露再到感染，然后进入预防性治疗、发病、未进入卫生保健系统或漏诊/误诊，并标有卫生保健机构筛查和关怀模式的PICO标签。下方为图2，是由四个相连方框组成的逻辑模型：投入（如利益攸关方参与、财力和人力资源、研究证据）、活动（如接触者调查、结核病筛查、诊断方法、治疗方案、关怀模式）、短期结果（如更早发现药物敏感和耐药结核病、改善治疗结果、提高预防性治疗覆盖率）和长期结果（降低结核病发病率、死亡率、结核病后遗症和经济损失）。",
        "es": "Representación de una página que muestra la parte inferior de la figura 1, una cascada de atención de la tuberculosis en niños y adolescentes dibujada como trayectorias ramificadas desde susceptible a expuesto e infectado, y de ahí a tratamiento preventivo, enfermedad, sin acceso al sistema de salud o sin diagnóstico/mal diagnosticado, con etiquetas PICO para el cribado en establecimientos de salud y los modelos de atención. Debajo, la figura 2 es un modelo lógico de cuatro recuadros enlazados: insumos (p. ej., participación de las partes interesadas, recursos financieros y humanos, evidencia de investigaciones), actividades (p. ej., investigación de contactos, cribado de la tuberculosis, enfoques diagnósticos, pautas de tratamiento, modelos de atención), resultados a corto plazo (p. ej., detección más temprana de la tuberculosis farmacosensible y farmacorresistente, mejores resultados del tratamiento, mayor cobertura del tratamiento preventivo) y resultados a largo plazo (reducción de la incidencia, la mortalidad, las secuelas postuberculosas y las pérdidas económicas).",
        "fr": "Rendu d'une page montrant la partie inférieure de la figure 1, une cascade des soins de la tuberculose chez l'enfant et l'adolescent dessinée sous forme de trajectoires ramifiées allant de sensible à exposé puis infecté, puis vers le traitement préventif, la maladie, l'absence d'accès au système de santé ou l'absence de diagnostic/le diagnostic erroné, avec des étiquettes PICO pour le dépistage dans les établissements de santé et les modèles de soins. En dessous, la figure 2 est un modèle logique de quatre cases reliées : intrants (p. ex. mobilisation des parties prenantes, ressources financières et humaines, données de la recherche), activités (p. ex. recherche des contacts, dépistage de la tuberculose, approches diagnostiques, schémas thérapeutiques, modèles de soins), résultats à court terme (p. ex. détection plus précoce de la tuberculose pharmacosensible et pharmacorésistante, meilleurs résultats thérapeutiques, couverture accrue du traitement préventif) et résultats à long terme (réduction de l'incidence, de la mortalité, des séquelles post-tuberculose et des pertes financières).",
        "ru": "Изображение страницы: нижняя часть рисунка 1 — каскад помощи при ТБ у детей и подростков в виде разветвляющихся путей от восприимчивых к контактировавшим и инфицированным, а затем к профилактическому лечению, заболеванию, отсутствию обращения в систему здравоохранения или невыявлению/ошибочной диагностике, с метками PICO для скрининга в медицинских учреждениях и моделей оказания помощи. Ниже — рисунок 2, логическая модель из четырех связанных блоков: вводимые ресурсы (например, вовлечение заинтересованных сторон, финансовые и кадровые ресурсы, данные исследований), мероприятия (например, обследование контактов, скрининг на ТБ, диагностические подходы, схемы лечения, модели оказания помощи), краткосрочные результаты (например, более раннее выявление лекарственно-чувствительного и лекарственно-устойчивого ТБ, улучшение исходов лечения, расширение охвата профилактическим лечением) и долгосрочные результаты (снижение заболеваемости ТБ, смертности, последствий перенесенного ТБ и финансовых потерь)."
      },
      "state": "draft"
    }
  ],
  "tables": [
    {
      "label": "Table 1",
      "caption": "Table 1: New recommendations in the WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents, 2022",
      "pages": [
        20,
        21
      ],
      "columns": [
        {
          "titles": "No."
        },
        {
          "titles": "Recommendation"
        }
      ],
      "rows": [
        [
          "Diagnostic approaches",
          ""
        ],
        [
          "1",
          "In children with signs and symptoms of pulmonary TB, Xpert Ultra should be used as the initial diagnostic test for TB and detection of rifampicin resistance on sputum, nasopharyngeal aspirate, gastric aspirate or stool, rather than smear microscopy/culture and phenotypic drug susceptibility testing (DST). (UPDATED: strong recommendation, moderate certainty of evidence for test accuracy in stool and gastric aspirate; low certainty of evidence for test accuracy in sputum; very low certainty of evidence for test accuracy in nasopharyngeal aspirate)"
        ],
        [
          "2",
          "In children with presumptive pulmonary TB attending health care facilities, integrated treatment decision algorithms may be used to diagnose pulmonary TB. (NEW: interim, conditional recommendation, very low certainty of evidence)"
        ],
        [
          "Treatment regimens",
          ""
        ],
        [
          "3",
          "In children and adolescents between 3 months and 16 years of age with non-severe TB (without suspicion or evidence of multidrug- or rifampicin-resistant TB (MDR/RR-TB), a 4-month treatment regimen (2HRZ(E)/2HR) should be used. (NEW: strong recommendation, moderate certainty of evidence)"
        ],
        [
          "4",
          "In children with MDR/RR-TB aged below 6 years, an all-oral treatment regimen containing bedaquiline may be used. (NEW: conditional recommendation, very low certainty of evidence)¹⁴"
        ],
        [
          "5",
          "In children with MDR/RR-TB aged below 3 years delamanid may be used as part of longer regimens. (NEW: conditional recommendation, very low certainty of evidence)¹⁵"
        ],
        [
          "6",
          "In children and adolescents with bacteriologically confirmed or clinically diagnosed TB meningitis (without suspicion or evidence of MDR/RR-TB), a 6-month intensive regimen (6HRZEto) may be used as an alternative option to the 12-month regimen (2HRZE/10HR). (NEW: conditional recommendation, very low certainty of evidence)"
        ],
        [
          "Models of TB care",
          ""
        ],
        [
          "7",
          "In high TB burden settings, decentralized TB services may be used in children and adolescents with signs and symptoms of TB and/or in those exposed to TB. (NEW: conditional recommendation, very low certainty of evidence)"
        ],
        [
          "8",
          "Family-centred, integrated services in addition to standard TB services may be used in children and adolescents with signs and symptoms of TB and/or those exposed to TB. (NEW: conditional recommendation, very low certainty of evidence)"
        ]
      ],
      "notes": "¹⁴ This recommendation applies to and complements the 2020 WHO recommendations on shorter and longer regimens that contain bedaquiline: A shorter all-oral bedaquiline-containing regimen of 9–12 months duration is recommended in eligible patients with confirmed multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) who have not been exposed to treatment with second-line TB medicines used in this regimen for more than one month, and in whom resistance to fluoroquinolones has been excluded (Conditional recommendation, very low certainty in the evidence); bedaquiline should be included in longer multidrug-resistant TB (MDR-TB) regimens for patients aged 18 years or more (Strong recommendation, moderate certainty in the estimates of effect); bedaquiline may also be included in longer MDR-TB regimens for patients aged 6–17 years; (Conditional recommendation, very low certainty in the estimates of effect) (9). ¹⁵ This recommendation complements the 2020 WHO recommendation on longer regimens that contain delamanid: Delamanid may be included in the treatment of MDR/RR-TB patients aged 3 years or more on longer regimens (Conditional recommendation, moderate certainty in the estimates of effect) (9). [Transcriber: the table has no column header; the 'No.' and 'Recommendation' column titles are supplied.]",
      "narratives": {
        "en": "The table lists the eight new or updated recommendations on the management of TB in children and adolescents from the 2022 WHO consolidated guidelines, grouped under diagnostic approaches, treatment regimens and models of TB care. Each recommendation is followed by its status (new or updated), strength and certainty of evidence.",
        "ar": "يسرد الجدول التوصيات الثماني الجديدة أو المحدَّثة بشأن تدبير السل لدى الأطفال والمراهقين الواردة في المبادئ التوجيهية الموحدة للمنظمة لعام 2022، مصنفةً تحت النُهج التشخيصية ونظم العلاج ونماذج رعاية مرضى السل. وتُتبع كل توصية بحالتها (جديدة أو محدَّثة) وقوتها ودرجة اليقين في البيّنات.",
        "zh": "本表列出世卫组织2022年综合指南中关于儿童和青少年结核病管理的八项新的或更新的建议，分为诊断方法、治疗方案和结核病医护模式三组。每项建议后均注明其状态（新的或更新的）、建议强度和证据确定性。",
        "es": "El cuadro enumera las ocho recomendaciones nuevas o actualizadas sobre el manejo de la tuberculosis en niños y adolescentes de las directrices unificadas de la OMS de 2022, agrupadas en métodos de diagnóstico, pautas de tratamiento y modelos de atención de la tuberculosis. Cada recomendación va seguida de su condición (nueva o actualizada), su fuerza y la certeza de la evidencia.",
        "fr": "Le tableau énumère les huit recommandations nouvelles ou mises à jour sur la prise en charge de la tuberculose chez l’enfant et l’adolescent issues des lignes directrices unifiées de l’OMS de 2022, regroupées sous approches diagnostiques, schémas thérapeutiques et modèles de soins antituberculeux. Chaque recommandation est suivie de son statut (nouvelle ou mise à jour), de sa force et du degré de certitude des données.",
        "ru": "В таблице перечислены восемь новых или обновленных рекомендаций по ведению туберкулеза у детей и подростков из сводного руководства ВОЗ 2022 г., сгруппированных по разделам: диагностические подходы, схемы лечения и модели оказания помощи при туберкулезе. После каждой рекомендации указаны ее статус (новая или обновленная), сила и степень достоверности данных."
      },
      "csv": "tables/table-1.csv"
    },
    {
      "label": "Table 2",
      "caption": "Table 2: Recommendations in the WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents, 2022, by chapter and topic",
      "pages": [
        21,
        22,
        23
      ],
      "columns": [
        {
          "titles": "Chapter"
        },
        {
          "titles": "Topic"
        }
      ],
      "rows": [
        [
          "Screening and contact investigation",
          "Screening for TB in targeted populations"
        ],
        [
          "",
          "Tools for screening for TB"
        ],
        [
          "",
          "HIV counselling and testing for household and close contacts of people with TB"
        ],
        [
          "Prevention",
          "TB infection prevention and control: administrative controls"
        ],
        [
          "",
          "TB infection prevention and control: environmental controls"
        ],
        [
          "",
          "TB infection prevention and control: respiratory protection"
        ],
        [
          "",
          "BCG vaccination: BCG vaccination at birth vs at six weeks"
        ],
        [
          "",
          "BCG vaccination: Selective BCG vaccination"
        ],
        [
          "",
          "BCG vaccination: Need for revaccination"
        ],
        [
          "",
          "BCG vaccination: BCG vaccination for HIV-infected infants"
        ],
        [
          "",
          "TB preventive treatment: Identifying populations for TB infection testing and TB preventive treatment – People living with HIV"
        ],
        [
          "",
          "TB preventive treatment: Identifying populations for TB infection testing and TB preventive treatment – Household contacts (regardless of HIV status)"
        ],
        [
          "",
          "TB preventive treatment: Identifying populations for TB infection testing and TB preventive treatment – Other people at risk"
        ],
        [
          "",
          "TB preventive treatment: Algorithms to rule out TB disease"
        ],
        [
          "",
          "TB preventive treatment: Testing for TB infection"
        ],
        [
          "",
          "TB preventive treatment: TB preventive treatment options"
        ],
        [
          "Diagnostic approaches",
          "Use of commercial serodiagnostics"
        ],
        [
          "",
          "Xpert MTB/RIF and Xpert Ultra as initial tests in adults and children with signs and symptoms of pulmonary TB"
        ],
        [
          "",
          "Xpert MTB/RIF and Xpert Ultra as initial tests in adolescents and children with signs and symptoms of extrapulmonary TB"
        ],
        [
          "",
          "Xpert MTB/RIF and Xpert Ultra repeated testing in children and adolescents with signs and symptoms of pulmonary TB"
        ],
        [
          "",
          "Xpert MTB/RIF and Xpert Ultra as initial tests for pulmonary TB in adults in the general population either with signs and symptoms of TB or chest radiography with lung abnormalities or both"
        ],
        [
          "",
          "Truenat MTB, MTB Plus and Truenat MTB-RIF Dx in adults and children with signs and symptoms of pulmonary TB"
        ],
        [
          "",
          "Moderate complexity automated nucleic acid amplification tests (NAATs) for detection of TB and resistance to rifampicin and isoniazid"
        ],
        [
          "",
          "Loop-mediated isothermal amplification"
        ],
        [
          "",
          "Lateral flow urine lipoarabinomannan (LF-LAM) assay"
        ],
        [
          "",
          "Low complexity NAATs for detection of resistance to isoniazid and second-line TB agents"
        ],
        [
          "",
          "First-line line-probe assay (LPAs)"
        ],
        [
          "",
          "Second-line line-probe assays (SL-LPAs)"
        ],
        [
          "",
          "High complexity reverse hybridization-based NAATs for detection of pyrazinamide resistance"
        ],
        [
          "Treatment",
          "Treatment of severe forms of pulmonary TB in children"
        ],
        [
          "",
          "Treatment of infants aged 0–3 months with TB"
        ],
        [
          "",
          "Treatment of osteoarticular TB in children"
        ],
        [
          "",
          "Use of thrice weekly dosing and fixed dose combination tablets"
        ],
        [
          "",
          "Use of corticosteroids in TB meningitis"
        ],
        [
          "",
          "A 4-month treatment regimen composed of isoniazid, rifapentine, moxifloxacin and pyrazinamide for treatment of drug-susceptible pulmonary TB"
        ],
        [
          "",
          "Regimen for rifampicin-susceptible and isoniazid-resistant TB"
        ],
        [
          "",
          "Shorter all-oral bedaquiline-containing regimen for multidrug- or rifampicin-resistant TB (MDR/RR-TB)"
        ],
        [
          "",
          "Longer regimens for MDR/RR-TB"
        ],
        [
          "",
          "The bedaquiline, pretomanid and linezolid (BPaL) regimen for MDR-TB with additional fluoroquinolone resistance"
        ],
        [
          "",
          "Monitoring patient response to MDR-TB treatment using culture"
        ],
        [
          "Models of TB care",
          "Health education and counselling"
        ],
        [
          "",
          "Treatment adherence interventions"
        ],
        [
          "",
          "Treatment administration options"
        ],
        [
          "",
          "Ambulatory care for persons with MDR-TB"
        ],
        [
          "",
          "Decentralized model of care for persons with MDR-TB"
        ],
        [
          "Special situations",
          "Routine HIV testing for persons with presumptive and diagnosed TB"
        ],
        [
          "",
          "Co-trimoxazole prophylaxis for infants, children and adolescents living with HIV"
        ],
        [
          "",
          "General recommendations on eligibility for ART"
        ],
        [
          "",
          "Timing of ART for children and adolescents with TB"
        ],
        [
          "",
          "First-line ART regimens"
        ],
        [
          "",
          "Second-line ART regimens"
        ],
        [
          "",
          "Management of severe acute malnutrition (SAM)"
        ],
        [
          "",
          "Management of moderate undernutrition"
        ],
        [
          "",
          "Contact investigation"
        ]
      ],
      "narratives": {
        "en": "The table lists the topics covered by recommendations in the 2022 WHO consolidated guidelines on the management of TB in children and adolescents, by chapter: screening and contact investigation, prevention, diagnostic approaches, treatment, models of TB care and special situations.",
        "ar": "يسرد الجدول المواضيع التي تتناولها التوصيات الواردة في المبادئ التوجيهية الموحدة للمنظمة لعام 2022 بشأن تدبير السل لدى الأطفال والمراهقين، حسب الفصل: التحري وتقصي المخالطين، والوقاية، والنُهج التشخيصية، والعلاج، ونماذج رعاية مرضى السل، والحالات الخاصة.",
        "zh": "本表按章节列出世卫组织2022年儿童和青少年结核病管理综合指南中建议所涵盖的主题：筛查和接触者调查、预防、诊断方法、治疗、结核病医护模式以及特殊情况。",
        "es": "El cuadro enumera, por capítulo, los temas abarcados por las recomendaciones de las directrices unificadas de la OMS de 2022 sobre el manejo de la tuberculosis en niños y adolescentes: cribado e investigación de contactos, prevención, métodos de diagnóstico, tratamiento, modelos de atención de la tuberculosis y situaciones especiales.",
        "fr": "Le tableau énumère, par chapitre, les thèmes couverts par les recommandations des lignes directrices unifiées de l’OMS de 2022 sur la prise en charge de la tuberculose chez l’enfant et l’adolescent : dépistage et recherche des contacts, prévention, approches diagnostiques, traitement, modèles de soins antituberculeux et situations particulières.",
        "ru": "В таблице по главам перечислены темы, охваченные рекомендациями сводного руководства ВОЗ 2022 г. по ведению туберкулеза у детей и подростков: скрининг и обследование контактов, профилактика, диагностические подходы, лечение, модели оказания помощи при туберкулезе и особые ситуации."
      },
      "csv": "tables/table-2.csv"
    },
    {
      "label": "Table 3",
      "caption": "Table 3: WHO recommendations on TB screening and contact investigation relevant to children and adolescents",
      "pages": [
        33,
        34
      ],
      "columns": [
        {
          "titles": ""
        }
      ],
      "rows": [
        [
          "WHO consolidated guidelines on tuberculosis. Module 2: screening – systematic screening for tuberculosis disease (11)"
        ],
        [
          "Screening for TB in targeted populations"
        ],
        [
          "Household contacts and other close contacts of individuals with TB disease should be systematically screened for TB disease. (Strong recommendation, moderate certainty of evidence)"
        ],
        [
          "People living with HIV should be systematically screened for TB disease at each visit to a health facility. (Strong recommendation, very low certainty of evidence)"
        ],
        [
          "Systematic screening for TB disease may be conducted among subpopulations with structural risk factors for TB. These include urban poor communities, homeless communities, communities in remote or isolated areas, indigenous populations, migrants, refugees, internally displaced persons and other vulnerable or marginalized groups with limited access to health care. (Existing recommendation: conditional recommendation, very low certainty of evidence)."
        ],
        [
          "Tools for screening for TB"
        ],
        [
          "Among individuals aged 15 years and older in populations in which TB screening is recommended, systematic screening for TB disease may be conducted using a symptom screen, chest X-ray or molecular WHO-recommended rapid diagnostic tests, alone or in combination. (Conditional recommendation, very low certainty of evidence for test accuracy)"
        ],
        [
          "Among individuals aged 15 years and older in populations in which TB screening is recommended, computer-aided detection software programmes may be used in place of human readers for interpreting digital chest X-rays for screening and triage for TB disease. (Conditional recommendation, low certainty of evidence)"
        ],
        [
          "Among adults and adolescents living with HIV, systematic screening for TB disease should be conducted using the WHO-recommended four symptom screen and those who report any one of the symptoms of current cough, fever, weight loss or night sweats may have TB and should be evaluated for TB and other diseases. (Strong recommendation, moderate certainty of evidence)"
        ],
        [
          "Among adults and adolescents living with HIV, C-reactive protein using a cut-off of >5 mg/L may be used to screen for TB disease. (Conditional recommendation, low certainty of evidence for test accuracy)"
        ],
        [
          "Among adults and adolescents living with HIV, chest X-ray may be used to screen for TB disease. (Conditional recommendation, moderate certainty of evidence for test accuracy)"
        ],
        [
          "Among adults and adolescents living with HIV, molecular WHO-recommended rapid diagnostic tests may be used to screen for TB disease. (Conditional recommendation, moderate certainty of evidence for test accuracy)"
        ],
        [
          "Adult and adolescent inpatients with HIV in medical wards where the TB prevalence is >10% should be tested systematically for TB disease with a molecular WHO-recommended rapid diagnostic test. (Strong recommendation, moderate certainty of evidence for test accuracy)"
        ],
        [
          "Among individuals younger than 15 years who are close contacts of someone with TB, systematic screening for TB disease should be conducted using a symptom screen including any one of cough, fever or poor weight gain; or chest radiography; or both. (Strong recommendation, moderate to low certainty of evidence for test accuracy)"
        ],
        [
          "Among children younger than 10 years who are living with HIV, systematic screening for TB disease should be conducted using a symptom screen including any one of current cough, fever, poor weight gain or close contact with a TB patient. (Strong recommendation, low certainty of evidence for test accuracy)"
        ],
        [
          "Guidance for national tuberculosis programmes on the management of tuberculosis in children. Second edition (8)"
        ],
        [
          "In settings of high HIV prevalence, all household and close contacts of people with TB should be counselled and tested for HIV. (Strong recommendation, very low certainty of evidence)"
        ],
        [
          "In settings of low HIV prevalence, all household members and close contacts of people with TB who have symptoms compatible with TB disease may be offered counselling and testing for HIV as part of their clinical evaluation. (Conditional recommendation, very low certainty of evidence)"
        ],
        [
          "All household contacts of an index case who is a person living with HIV should be counselled and tested for HIV. (Strong recommendation, very low certainty of evidence)"
        ]
      ],
      "notes": "[Transcriber: single-column table; rows include the source-guideline headings and topic subheadings as printed, followed by the recommendation cells.]",
      "narratives": {
        "en": "The table compiles current WHO recommendations on TB screening and contact investigation that apply to children and adolescents. Recommendations are grouped by source guideline and topic (screening in targeted populations, tools for screening, HIV counselling and testing of contacts), each with its strength and certainty of evidence.",
        "ar": "يجمع الجدول توصيات المنظمة الحالية بشأن تحري السل وتقصي المخالطين التي تنطبق على الأطفال والمراهقين. والتوصيات مصنفة حسب المبدأ التوجيهي المصدر والموضوع (التحري في فئات سكانية مستهدفة، وأدوات التحري، وتقديم المشورة بشأن فيروس العوز المناعي البشري واختباره للمخالطين)، مع بيان قوة كل توصية ودرجة اليقين في البيّنات.",
        "zh": "本表汇集适用于儿童和青少年的现行世卫组织结核病筛查和接触者调查建议。建议按来源指南和主题（目标人群筛查、筛查工具、接触者艾滋病毒咨询和检测）分组，并注明每项建议的强度和证据确定性。",
        "es": "El cuadro reúne las recomendaciones vigentes de la OMS sobre cribado de la tuberculosis e investigación de contactos aplicables a niños y adolescentes. Las recomendaciones se agrupan por directriz de origen y tema (cribado en poblaciones destinatarias, instrumentos de cribado, asesoramiento y pruebas del VIH para los contactos), con su fuerza y la certeza de la evidencia.",
        "fr": "Le tableau rassemble les recommandations actuelles de l’OMS sur le dépistage de la tuberculose et la recherche des contacts qui s’appliquent aux enfants et aux adolescents. Elles sont regroupées par ligne directrice source et par thème (dépistage dans des populations cibles, outils de dépistage, conseil et dépistage du VIH pour les contacts), avec leur force et le degré de certitude des données.",
        "ru": "В таблице собраны действующие рекомендации ВОЗ по скринингу на туберкулез и обследованию контактов, применимые к детям и подросткам. Рекомендации сгруппированы по исходному руководству и теме (скрининг в целевых группах, инструменты скрининга, консультирование и тестирование контактов на ВИЧ) с указанием их силы и степени достоверности данных."
      },
      "csv": "tables/table-3.csv"
    },
    {
      "label": "Table 4",
      "caption": "Table 4: WHO recommendations on TB infection prevention and control, BCG vaccination and TPT relevant to children and adolescents",
      "pages": [
        35,
        36,
        37,
        38,
        39
      ],
      "columns": [
        {
          "titles": ""
        }
      ],
      "rows": [
        [
          "TB infection prevention and control: WHO guidelines on tuberculosis infection prevention and control, 2019 update (12)"
        ],
        [
          "Administrative controls"
        ],
        [
          "Triage of people with TB signs and symptoms, or with TB disease, is recommended to reduce M. tuberculosis transmission to health workers (including community health workers (CHW)), persons attending health care facilities or other persons in settings with a high risk of transmission. (Conditional recommendation, very low certainty in the estimates of effects)"
        ],
        [
          "Respiratory separation/isolation of people with presumed or demonstrated infectious TB is recommended to reduce M. tuberculosis transmission to health workers or other persons attending health care facilities. (Conditional recommendation, very low certainty in the estimates of effects)"
        ],
        [
          "Prompt initiation of effective TB treatment of people with TB disease is recommended to reduce M. tuberculosis transmission to health workers, persons attending health care facilities or other persons in settings with a high risk of transmission. (Strong recommendation, very low certainty in the estimates of effects)"
        ],
        [
          "Respiratory hygiene (including cough etiquette) in people with presumed or confirmed TB is recommended to reduce M. tuberculosis transmission to health workers, persons attending health care facilities or other persons in settings with a high risk of transmission. (Strong recommendation, low certainty in the estimates of effects)"
        ],
        [
          "Environmental controls"
        ],
        [
          "Upper-room germicidal ultraviolet (GUV) systems are recommended to reduce M. tuberculosis transmission to health workers, persons attending health care facilities or other persons in settings with a high risk of transmission. (Conditional recommendation, moderate certainty in the estimates of effects)"
        ],
        [
          "Ventilation systems (including natural, mixed-mode, mechanical ventilation and recirculated air through high-efficiency particulate air (HEPA) filters) are recommended to reduce M. tuberculosis transmission to health workers, persons attending health care facilities or other persons in settings with a high risk of transmission. (Conditional recommendation, very low certainty in the estimates of effects)"
        ],
        [
          "Respiratory protection"
        ],
        [
          "Particulate respirators, within the framework of a respiratory protection programme, are recommended to reduce M. tuberculosis transmission to health workers, persons attending health care facilities or other persons in settings with a high risk of transmission. (Conditional recommendation, very low certainty in the estimates of effects)"
        ],
        [
          "BCG vaccination: BCG vaccines: WHO position paper, 2018 (13)"
        ],
        [
          "Bacillus Calmette-Guérin (BCG) vaccination at birth vs at 6 weeks"
        ],
        [
          "In countries or settings with a high incidence of TB and/or leprosy, a single dose of BCG vaccine should be given to neonates at birth, or as soon as possible thereafter, for prevention of TB and leprosy disease. If it cannot be given at birth, it should be given at the earliest opportunity thereafter and should not be delayed. Any delay in vaccination may lead to opportunities for known or unknown exposure to TB or leprosy-infected contacts. Co-administration of BCG with the hepatitis B birth dose is safe and strongly recommended. In order to avoid missed opportunities for neonatal vaccination, BCG multi-dose vials should be opened and used despite any wastage of unused vaccine. If the birth dose was missed, catch-up vaccination of unvaccinated older infants and children is recommended since evidence shows it is beneficial. Catch-up vaccination should be done at the earliest convenient encounter with the health care system to minimize known or unknown exposure to TB or leprosy infected contacts."
        ],
        [
          "Selective BCG vaccination"
        ],
        [
          "Countries with a low incidence of TB or leprosy may choose to selectively vaccinate neonates in recognized risk groups for developing disease. High-risk groups to be considered for BCG vaccination include the following: • Neonates to parents (or other close contacts/relatives) with previous TB or leprosy • Neonates in households with contacts to countries with high incidence of TB and/or leprosy • Neonates in any other locally identified risk group for TB and/or leprosy In a few countries with low TB incidence, BCG vaccination is largely replaced by intensified case detection, contact tracing and supervised early treatment."
        ],
        [
          "Need for revaccination"
        ],
        [
          "Studies show minimal or no evidence of any additional benefit of repeat BCG vaccination against TB or leprosy. Therefore, revaccination is not recommended even if the TST reaction or result of an IGRA is negative. The absence of a BCG scar after vaccination is not indicative of a lack of protection and is not an indication for revaccination."
        ],
        [
          "BCG vaccination for HIV-infected infants"
        ],
        [
          "Children who are HIV-infected when vaccinated with BCG at birth are at increased risk of developing disseminated BCG disease. However, if HIV-infected individuals including children, are receiving ART, are clinically well and immunologically stable (CD4% >25% for children aged <5 years or CD4 count ≥200 if aged >5 years) they should be vaccinated with BCG. • In general, populations with high prevalence of HIV infection also have the greatest burden of TB; in such populations the benefits of potentially preventing severe TB through vaccination at birth are outweighed by the risks associated with the use of BCG vaccine. Therefore, it is recommended that in such populations: – Neonates born to women of unknown HIV status should be vaccinated as the benefits of BCG vaccination outweigh the risks. – Neonates of unknown HIV status born to HIV-infected women should be vaccinated if they have no clinical evidence suggestive of HIV infection, regardless of whether the mother is receiving ART. – Although evidence is limited, for neonates with HIV infection confirmed by early virological testing, BCG vaccination should be delayed until ART has been started and the infant confirmed to be clinically and immunologically stable (CD4% >25%)."
        ],
        [
          "TB preventive treatment: WHO consolidated guidelines on tuberculosis. Module 1 – prevention – tuberculosis preventive treatment, 2020 (14)"
        ],
        [
          "Identifying populations for TB infection testing and TPT – people living with HIV"
        ],
        [
          "Adults and adolescents living with HIV who are unlikely to have TB disease should receive TB preventive treatment as part of a comprehensive package of HIV care. Treatment should also be given to those on antiretroviral treatment, to pregnant women and to those who have previously been treated for TB, irrespective of the degree of immunosuppression and even if TB infection testing is unavailable. (Strong recommendation, high certainty in the estimates of effect)"
        ],
        [
          "Infants aged <12 months living with HIV who are in contact with a person with TB and who are unlikely to have TB disease on an appropriate clinical evaluation or according to national guidelines should receive TB preventive treatment. (Strong recommendation, moderate certainty in the estimates of effect)"
        ],
        [
          "Children aged ≥12 months living with HIV who are considered unlikely to have TB disease on an appropriate clinical evaluation or according to national guidelines should be offered TB preventive treatment as part of a comprehensive package of HIV prevention and care if they live in a setting with high TB transmission, regardless of contact with TB. (Strong recommendation, low certainty in the estimates of effect)"
        ],
        [
          "All children living with HIV who have successfully completed treatment for TB disease may receive TB preventive treatment. (Conditional recommendation, low certainty in the estimates of effect)"
        ],
        [
          "Identifying populations for TB infection testing and TB preventive treatment – household contacts (regardless of HIV status)"
        ],
        [
          "Children aged <5 years who are household contacts of people with bacteriologically confirmed pulmonary TB and who are found not to have TB disease on an appropriate clinical evaluation or according to national guidelines should be given TB preventive treatment even if TB infection testing is unavailable. (Strong recommendation, high certainty in the estimates of effect)"
        ],
        [
          "Children aged ≥5 years adolescents and adults who are household contacts of people with bacteriologically confirmed pulmonary TB who are found not to have TB disease by an appropriate clinical evaluation or according to national guidelines may be given TB preventive treatment. (Conditional recommendation, low certainty in the estimates of effect)"
        ],
        [
          "In selected high-risk household contacts of patients with multidrug-resistant tuberculosis, preventive treatment may be considered based on individualized risk assessment and a sound clinical justification. (Conditional recommendation, very low certainty in the estimates of effect)"
        ],
        [
          "Identifying populations for TB infection testing and TB preventive treatment – other people at risk (these populations may include children and adolescents)"
        ],
        [
          "People who are initiating anti-TNF²⁰ treatment, or receiving dialysis, or preparing for an organ or haematological transplant, or who have silicosis should be systematically tested and treated for TB infection. (Strong recommendation, low to very low certainty in the estimates of effect)"
        ],
        [
          "Systematic TB infection testing and treatment may be considered for prisoners, health workers, immigrants from countries with a high TB burden, homeless people and people who use drugs. (Conditional recommendation, low to very low certainty in the estimates of effect)"
        ],
        [
          "Systematic TB infection testing and treatment is not recommended for people with diabetes, people who engage in the harmful use of alcohol, tobacco smokers and underweight people unless they also belong to other risk groups included in the above recommendations. (Conditional recommendation, very low certainty in the estimates of effect)"
        ],
        [
          "Algorithms to rule out TB disease"
        ],
        [
          "Adults and adolescents living with HIV should be screened for TB according to a clinical algorithm. Those who do not report any of the symptoms of current cough, fever, weight loss or night sweats are unlikely to have TB disease and should be offered preventive treatment, regardless of their antiretroviral treatment (ART) status. (Strong recommendation, moderate certainty in the estimates of effect)"
        ],
        [
          "Adults and adolescents living with HIV who are screened for TB according to a clinical algorithm and who report any of the symptoms of current cough, fever, weight loss or night sweats may have TB disease and should be evaluated for TB and other diseases and offered preventive treatment if TB disease is excluded. (Strong recommendation, moderate certainty in the estimates of effect)"
        ],
        [
          "Chest radiography may be offered to people living with HIV on ART and preventive treatment given to those with no abnormal radiographic findings. (Conditional recommendation, low certainty in the estimates of effect)"
        ],
        [
          "Infants and children living with HIV who have poor weight gain, fever or current cough or who have a history of contact with a person with TB should be evaluated for TB and other diseases that cause such symptoms. If TB disease is excluded after an appropriate clinical evaluation or according to national guidelines, these children should be offered TB preventive treatment, regardless of their age. (Strong recommendation, low certainty in the estimates of effect)"
        ],
        [
          "The absence of any symptoms of TB and the absence of abnormal chest radiographic findings may be used to rule out TB disease among HIV-negative household contacts aged ≥5 years and other risk groups before preventive treatment. (Conditional recommendation, very low certainty in the estimates of effect)"
        ],
        [
          "Testing for TB infection"
        ],
        [
          "Either a tuberculin skin test (TST) or interferon-gamma release assay (IGRA) can be used to test for TB infection. (Strong recommendation, very low certainty in the estimates of effect)"
        ],
        [
          "TB preventive treatment options"
        ],
        [
          "The following options are recommended for the treatment of TB infection regardless of HIV status: 6 or 9 months of daily isoniazid, or a 3-month regimen of weekly rifapentine plus isoniazid,²¹ or a 3-month regimen of daily isoniazid plus rifampicin. (strong recommendation, moderate to high certainty in the estimates of effect). A 1-month regimen of daily rifapentine plus isoniazid²² or 4 months of daily rifampicin alone may also be offered as alternatives. (Conditional recommendation, low to moderate certainty in the estimates of effect)"
        ],
        [
          "In settings with high TB transmission, adults and adolescents living with HIV who have an unknown or a positive TB infection test, and are unlikely to have TB disease, should receive at least 36 months of daily isoniazid preventive therapy (IPT). Daily IPT for 36 months should be given whether or not the person is on ART, and irrespective of the degree of immunosuppression, history of previous TB treatment and pregnancy in settings considered to have a high TB transmission as defined by national authorities. (Conditional recommendation, low certainty in the estimates of effect)"
        ]
      ],
      "notes": "²⁰ TNF: tumour necrosis factor ²¹ In children 2 years and above. ²² In children 13 years and above. [Transcriber: single-column table; rows include the source-guideline headings and topic subheadings as printed, followed by the recommendation cells.]",
      "narratives": {
        "en": "The table compiles current WHO recommendations relevant to children and adolescents on TB infection prevention and control (administrative, environmental and respiratory protection controls), BCG vaccination and TB preventive treatment. Recommendations are grouped by source guideline and topic, with their strength and certainty of evidence where given.",
        "ar": "يجمع الجدول توصيات المنظمة الحالية ذات الصلة بالأطفال والمراهقين بشأن الوقاية من عدوى السل ومكافحتها (الضوابط الإدارية والبيئية وضوابط الحماية التنفسية)، والتطعيم بلقاح BCG، والعلاج الوقائي من السل. والتوصيات مصنفة حسب المبدأ التوجيهي المصدر والموضوع، مع بيان قوتها ودرجة اليقين في البيّنات حيثما وردت.",
        "zh": "本表汇集与儿童和青少年相关的现行世卫组织建议，涉及结核感染预防和控制（行政控制、环境控制和呼吸防护）、卡介苗接种以及结核病预防性治疗。建议按来源指南和主题分组，并在有说明时注明其强度和证据确定性。",
        "es": "El cuadro reúne las recomendaciones vigentes de la OMS pertinentes para niños y adolescentes sobre prevención y control de la infección tuberculosa (controles administrativos, ambientales y de protección respiratoria), vacunación con BCG y tratamiento preventivo de la tuberculosis. Se agrupan por directriz de origen y tema, con su fuerza y la certeza de la evidencia cuando se indican.",
        "fr": "Le tableau rassemble les recommandations actuelles de l’OMS concernant les enfants et les adolescents en matière de prévention et de contrôle de l’infection tuberculeuse (mesures administratives, environnementales et de protection respiratoire), de vaccination par le BCG et de traitement préventif de la tuberculose. Elles sont regroupées par ligne directrice source et par thème, avec leur force et le degré de certitude des données lorsqu’ils sont indiqués.",
        "ru": "В таблице собраны действующие рекомендации ВОЗ, касающиеся детей и подростков, по профилактике туберкулезной инфекции и инфекционному контролю (административные меры, меры инженерного контроля и средства защиты органов дыхания), вакцинации БЦЖ и профилактическому лечению туберкулеза. Рекомендации сгруппированы по исходному руководству и теме с указанием их силы и степени достоверности данных, если они приводятся."
      },
      "csv": "tables/table-4.csv"
    },
    {
      "label": "Table 5",
      "caption": "Table 5: WHO recommendations on diagnostic approaches relevant to children and adolescents",
      "pages": [
        50,
        51,
        52,
        53,
        54
      ],
      "columns": [
        {
          "titles": ""
        }
      ],
      "rows": [
        [
          "WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection, 2021 update (16)"
        ],
        [
          "Recommendations on Xpert MTB/RIF and Xpert Ultra as initial tests in adults and children with signs and symptoms of pulmonary TB (Note that in these guidelines, adults refer to persons aged 15 years and above and children aged below 15 years, therefore the adult population includes older adolescents):"
        ],
        [
          "In adults* with signs and symptoms of pulmonary TB, Xpert MTB/RIF should be used as an initial diagnostic test for TB and rifampicin-resistance detection in sputum rather than smear microscopy/culture and phenotypic drug susceptibility testing (DST). (Strong recommendation, high certainty of evidence for test accuracy; moderate certainty of evidence for patient-important outcomes) * Adults and adolescents from 15 years"
        ],
        [
          "In children with signs and symptoms of pulmonary TB, Xpert MTB/RIF should be used as an initial diagnostic test for TB and rifampicin-resistance detection in sputum, gastric aspirate, nasopharyngeal aspirate and stool rather than smear microscopy/culture and phenotypic DST. (Strong recommendation, moderate certainty for accuracy in sputum; low certainty of evidence for test accuracy in gastric aspirate, nasopharyngeal aspirate and stool)"
        ],
        [
          "In adults* with signs and symptoms of pulmonary TB and without a prior history of TB (≤5 years) or with a remote history of TB treatment (>5 years since end of treatment), Xpert Ultra should be used as an initial diagnostic test for TB and for rifampicin-resistance detection in sputum, rather than smear microscopy/culture and phenotypic DST. (Strong recommendation, high certainty of evidence for test accuracy) * Adults and adolescents from 15 years"
        ],
        [
          "In adults* with signs and symptoms of pulmonary TB and with a prior history of TB and an end of treatment within the last 5 years, Xpert Ultra may be used as an initial diagnostic test for TB and for rifampicin-resistance detection in sputum, rather than smear microscopy/culture and phenotypic DST. (Conditional recommendation, low certainty of evidence for test accuracy) * Adults and adolescents from 15 years"
        ],
        [
          "Recommendations on Xpert MTB/RIF and Xpert Ultra as initial tests in adolescents and children with signs and symptoms of extrapulmonary TB"
        ],
        [
          "In adults and children with signs and symptoms of TB meningitis, Xpert MTB/RIF or Xpert Ultra should be used in cerebrospinal fluid (CSF) as an initial diagnostic test for TB meningitis rather than smear microscopy/culture. (Strong recommendation, moderate certainty of evidence for test accuracy for Xpert MTB/RIF; low certainty of evidence for test accuracy for Xpert Ultra)"
        ],
        [
          "In adults and children with signs and symptoms of extrapulmonary TB, Xpert MTB/RIF may be used in lymph node aspirate, lymph node biopsy, pleural fluid, peritoneal fluid, pericardial fluid, synovial fluid or urine specimens as the initial diagnostic test for respective form of extrapulmonary TB rather than smear microscopy/culture. (Conditional recommendation, moderate certainty of evidence for test accuracy for pleural fluid; low certainty for lymph node aspirate, peritoneal fluid, synovial fluid, urine; very low certainty for pericardial fluid, lymph nodes biopsy)"
        ],
        [
          "In adults and children with signs and symptoms of extrapulmonary TB, Xpert Ultra may be used in lymph node aspirate and lymph node biopsy as the initial diagnostic test for lymph nodes TB rather than smear microscopy/culture. (Conditional recommendation, low certainty of evidence)"
        ],
        [
          "In adults and children with signs and symptoms of extrapulmonary TB, Xpert MTB/RIF or Xpert Ultra should be used for rifampicin-resistance detection rather than culture and phenotypic DST. (Strong recommendation, high certainty of evidence for test accuracy for Xpert MTB/RIF; low certainty of evidence for Xpert Ultra)"
        ],
        [
          "In HIV-positive adults and children with signs and symptoms of disseminated TB, Xpert MTB/RIF may be used in blood, as an initial diagnostic test for disseminated TB. (Conditional recommendation, very low certainty of evidence for test accuracy)"
        ],
        [
          "Recommendations on Xpert MTB/RIF and Xpert Ultra repeated testing in children and adolescents with signs and symptoms of pulmonary TB"
        ],
        [
          "In adults* with signs and symptoms of pulmonary TB who have an Xpert Ultra trace positive result on the initial test, repeated testing with Xpert Ultra may not be used. (Conditional recommendation, very low certainty of evidence for test accuracy) Remark: Xpert Ultra trace results in adolescents will require follow-up, including reassessing clinical symptoms and information on prior history of TB. In the case of suspected rifampicin resistance, repeated testing may provide additional benefit for detection as well as an initial attempt to assess rifampicin resistance. For interpretation of trace results in children, see section 4.1.3. * Adults and adolescents from 15 years"
        ],
        [
          "In children with signs and symptoms of pulmonary TB in settings with pretest probability below 5% and an Xpert MTB/RIF negative result on the initial test, repeated testing with Xpert MTB/RIF in sputum, gastric fluid, nasopharyngeal aspirate or stool specimens may not be used. (Conditional recommendation, low certainty of evidence for test accuracy for sputum; and very low for other specimen types)"
        ],
        [
          "In children with signs and symptoms of pulmonary TB in settings with pretest probability 5% or more and an Xpert MTB/RIF negative result on the initial test, repeated testing with Xpert MTB/RIF (for total of two tests) in sputum, gastric fluid, nasopharyngeal aspirate and stool specimens may be used. (Conditional recommendation, low certainty of evidence for test accuracy for sputum; and very low for other specimen types)"
        ],
        [
          "In children with signs and symptoms of pulmonary TB in settings with pretest probability below 5% and an Xpert Ultra negative result on the initial test, repeated testing with Xpert Ultra in sputum or nasopharyngeal aspirate specimens may not be used. (Conditional recommendation, very low certainty of evidence for test accuracy)"
        ],
        [
          "In children with signs and symptoms of pulmonary TB in settings with pretest probability 5% or more and an Xpert Ultra negative result on the first initial test, repeated one Xpert Ultra test (for a total of two tests) in sputum and nasopharyngeal aspirate specimens may be used. (Conditional recommendation, very low certainty of evidence for test accuracy)"
        ],
        [
          "Recommendations on Xpert MTB/RIF and Xpert Ultra as initial tests for pulmonary TB in adults in the general population either with signs and symptoms of TB or chest radiograph with lung abnormalities or both"
        ],
        [
          "In adults* in the general population who had either signs or symptoms of TB or chest radiograph with lung abnormalities or both, the Xpert MTB/RIF or Xpert Ultra may replace culture as the initial test for pulmonary TB. (Conditional recommendation, low certainty of the evidence in test accuracy for Xpert MTB/RIF; and moderate certainty for Xpert Ultra) * Adults and adolescents from 15 years"
        ],
        [
          "In adults* in the general population who had either a positive TB symptom screen or chest radiograph with lung abnormalities or both, one Xpert Ultra test may be used rather than two Xpert Ultra tests as the initial test for pulmonary TB. (Conditional recommendation, very low certainty of evidence for test accuracy). * Adults and adolescents from 15 years"
        ],
        [
          "Truenat MTB, MTB Plus and Truenat MTB-RIF Dx in adults and children with signs and symptoms of pulmonary TB (specimen type: sputum)"
        ],
        [
          "In children and adults* with signs and symptoms of pulmonary TB, the Truenat MTB or MTB Plus may be used as an initial diagnostic test for TB rather than smear microscopy/culture. (Conditional recommendation, moderate certainty of evidence for test accuracy) * Adults and adolescents from 15 years"
        ],
        [
          "In children and adults* with signs and symptoms of pulmonary TB and a Truenat MTB or MTB Plus positive result, Truenat MTB-RIF Dx may be used as an initial test for rifampicin resistance rather than culture and phenotypic DST. (Conditional recommendation, very low certainty of evidence for test accuracy) * Adults and adolescents from 15 years"
        ],
        [
          "Moderate complexity automated nucleic acid amplification tests (NAATs) for detection of TB and resistance to rifampicin and isoniazid"
        ],
        [
          "In people with signs and symptoms of pulmonary TB, moderate complexity automated NAATs may be used on respiratory samples for the detection of pulmonary TB, and of rifampicin and isoniazid resistance, rather than culture and phenotypic DST. (Conditional recommendation, moderate certainty of evidence for diagnostic accuracy)"
        ],
        [
          "Loop-mediated isothermal amplification"
        ],
        [
          "TB-LAMP may be used as a replacement test for sputum-smear microscopy for diagnosing pulmonary TB in adults* with signs and symptoms consistent with TB. (Conditional recommendation, very low certainty evidence) * Adults and adolescents from 15 years"
        ],
        [
          "TB-LAMP may be used as a follow-on test to smear microscopy in adults* with signs and symptoms consistent with pulmonary TB, especially when further testing of sputum smear-negative specimens is necessary. (Conditional recommendation, very low certainty evidence) * Adults and adolescents from 15 years"
        ],
        [
          "Lateral flow urine lipoarabinomannan assay"
        ],
        [
          "In inpatient settings, WHO strongly recommends using LF-LAM to assist in the diagnosis of TB disease in HIV-positive adults and children: a. with signs and symptoms of TB (pulmonary and/or extrapulmonary) (strong recommendation, moderate certainty in the evidence about the intervention effects) or b. with advanced HIV disease or who are seriously ill (strong recommendation, moderate certainty in the evidence about the intervention effects); or c. irrespective of signs and symptoms of TB and with a CD4 cell count of less than 200 cells/mm³ (strong recommendation, moderate certainty in the evidence about the intervention effects)."
        ],
        [
          "In outpatient settings, WHO suggests using LF-LAM to assist in the diagnosis of TB disease in HIV-positive adults and children: a. with signs and symptoms of TB (pulmonary and/or extrapulmonary) or seriously ill (conditional recommendation, low certainty in the evidence about test accuracy); and b. irrespective of signs and symptoms of TB and with a CD4 cell count of less than 100 cells/mm³ (conditional recommendation, very low certainty in the evidence about test accuracy)"
        ],
        [
          "In outpatient settings, WHO recommends against using LF-LAM to assist in the diagnosis of TB disease in HIV-positive adults and children: a. without assessing TB symptoms (strong recommendation, very low certainty in the evidence about test accuracy); b. without TB symptoms and unknown CD4 cell count or without TB symptoms and CD4 cell count greater than or equal to 200 cells/mm³ (strong recommendation, very low certainty in the evidence about test accuracy); and c. without TB symptoms and with a CD4 cell count of 100–200 cells/mm³ (conditional recommendation, very low certainty in the evidence about test accuracy)."
        ],
        [
          "Low complexity NAATs for detection of resistance to isoniazid and second-line TB agents"
        ],
        [
          "In people with bacteriologically confirmed pulmonary TB, low complexity automated NAATs may be used on sputum for the initial detection of resistance to isoniazid and fluoroquinolones, rather than culture-based phenotypic DST. (Conditional recommendation, moderate certainty of evidence for diagnostic accuracy)"
        ],
        [
          "In people with bacteriologically confirmed pulmonary TB and resistance to rifampicin, low complexity automated NAATs may be used on sputum for the initial detection of resistance to ethionamide, rather than DNA sequencing of the inhA promoter. (Conditional recommendation, very low certainty of evidence for diagnostic accuracy)"
        ],
        [
          "In people with bacteriologically confirmed pulmonary TB and resistance to rifampicin, low complexity automated NAATs may be used on sputum for the initial detection of resistance to amikacin, rather than culture-based phenotypic DST. (Conditional recommendation, low certainty of evidence for diagnostic accuracy)"
        ],
        [
          "First-line line-probe assay (LPAs)"
        ],
        [
          "For persons with a sputum smear-positive specimen or a cultured isolate of Mycobacterium tuberculosis complex (MTBC), commercial molecular LPAs may be used as the initial test instead of phenotypic culture-based DST to detect resistance to rifampicin and isoniazid. (Conditional recommendation, moderate certainty in the evidence for the test’s accuracy)"
        ],
        [
          "Second-line line-probe assays (SL-LPAs)"
        ],
        [
          "For patients with confirmed MDR/RR-TB, SL-LPA may be used as the initial test, instead of phenotypic culture-based DST, to detect resistance to fluoroquinolones. (Conditional recommendation, moderate certainty in the evidence for test accuracy for direct testing of sputum specimens; low certainty in the evidence for test accuracy for indirect testing of Mycobacterium tuberculosis cultures)"
        ],
        [
          "For patients with confirmed MDR/RR-TB, SL-LPA may be used as the initial test, instead of phenotypic culture-based DST, to detect resistance to the second-line injectable drugs. (Conditional recommendation, low certainty in the evidence for test accuracy for direct testing of sputum specimens; very low certainty in the evidence for test accuracy for indirect testing of Mycobacterium tuberculosis cultures)"
        ],
        [
          "High complexity reverse hybridization-based NAATs for detection of pyrazinamide resistance"
        ],
        [
          "In people with bacteriologically confirmed TB, high complexity reverse hybridization-based NAATs may be used on M. tuberculosis culture isolates for detection of pyrazinamide resistance rather than culture-based phenotypic DST. (Conditional recommendation, very low certainty of evidence for diagnostic accuracy)"
        ],
        [
          "Commercial serodiagnostic tests for diagnosis of tuberculosis: policy statement, 2011 (17)"
        ],
        [
          "Commercial serodiagnostics should not be used in children suspected of active pulmonary or extrapulmonary TB, irrespective of their HIV status. (Strong recommendation, very low certainty of evidence for the use of commercial serodiagnostics)"
        ]
      ],
      "notes": "[Transcriber: single-column table; rows include the source-guideline headings and topic subheadings as printed, followed by the recommendation cells.]",
      "narratives": {
        "en": "The table compiles current WHO recommendations on diagnostic approaches relevant to children and adolescents, mainly on rapid molecular tests (Xpert MTB/RIF and Xpert Ultra, Truenat, NAATs, TB-LAMP, LF-LAM and line-probe assays) and on commercial serodiagnostics. Recommendations are grouped by source guideline and topic, each with its strength and certainty of evidence.",
        "ar": "يجمع الجدول توصيات المنظمة الحالية بشأن النُهج التشخيصية ذات الصلة بالأطفال والمراهقين، ولا سيما الاختبارات الجزيئية السريعة (Xpert MTB/RIF وXpert Ultra وTruenat واختبارات تضخيم الأحماض النووية وTB-LAMP وLF-LAM ومقايسات المسبار الخطي) والاختبارات المصلية التجارية. والتوصيات مصنفة حسب المبدأ التوجيهي المصدر والموضوع، مع بيان قوة كل توصية ودرجة اليقين في البيّنات.",
        "zh": "本表汇集与儿童和青少年相关的现行世卫组织诊断方法建议，主要涉及快速分子检测（Xpert MTB/RIF和Xpert Ultra、Truenat、核酸扩增试验、TB-LAMP、LF-LAM和线性探针检测）以及商业血清学诊断。建议按来源指南和主题分组，并注明每项建议的强度和证据确定性。",
        "es": "El cuadro reúne las recomendaciones vigentes de la OMS sobre métodos de diagnóstico pertinentes para niños y adolescentes, principalmente sobre pruebas moleculares rápidas (Xpert MTB/RIF y Xpert Ultra, Truenat, NAAT, TB-LAMP, LF-LAM y ensayos con sondas lineales) y sobre el serodiagnóstico comercial. Se agrupan por directriz de origen y tema, cada una con su fuerza y la certeza de la evidencia.",
        "fr": "Le tableau rassemble les recommandations actuelles de l’OMS sur les approches diagnostiques concernant les enfants et les adolescents, principalement sur les tests moléculaires rapides (Xpert MTB/RIF et Xpert Ultra, Truenat, TAAN, TB-LAMP, LF-LAM et tests par sondes en ligne) et sur les tests sérodiagnostiques commerciaux. Elles sont regroupées par ligne directrice source et par thème, avec leur force et le degré de certitude des données.",
        "ru": "В таблице собраны действующие рекомендации ВОЗ по диагностическим подходам, касающиеся детей и подростков, главным образом по быстрым молекулярным тестам (Xpert MTB/RIF и Xpert Ultra, Truenat, МАНК, TB-LAMP, LF-LAM и тесты гибридизации с типоспецифичными зондами) и коммерческим серодиагностическим тестам. Рекомендации сгруппированы по исходному руководству и теме с указанием их силы и степени достоверности данных."
      },
      "csv": "tables/table-5.csv"
    },
    {
      "label": "Table 6",
      "caption": "Table 6: WHO recommendations on TB treatment relevant to children and adolescents",
      "pages": [
        77,
        78,
        79,
        80
      ],
      "columns": [
        {
          "titles": ""
        }
      ],
      "rows": [
        [
          "Guidance for national tuberculosis programmes on the management of tuberculosis in children. Second edition, 2014 (8)"
        ],
        [
          "Children with pulmonary TB or tuberculous peripheral lymphadenitis who live in settings with low HIV prevalence and/or low prevalence of isoniazid resistance and children who are HIV-negative, can be treated with a three-drug regimen (HRZ) for 2 months followed by a two-drug (HR) regimen for 4 months at standard dosages. (Strong recommendation, moderate quality of evidence)"
        ],
        [
          "Children and adolescents with severe pulmonary disease should be treated with a four-drug regimen (HRZE) for 2 months followed by a two-drug regimen (HR) for 4 months at standard dosages. (Strong recommendation, moderate certainty of evidence)"
        ],
        [
          "Infants aged 0–3 months with suspected or confirmed pulmonary TB or tuberculous peripheral lymphadenitis should be promptly treated with the 6-month treatment regimen (2HRZ(E)/4HR). Treatment may require dose adjustment to reconcile the effect of age and possible toxicity in young infants. The decision to adjust doses should be taken by a clinician experienced in managing paediatric TB. (Strong recommendation, low certainty of evidence)"
        ],
        [
          "Children with suspected or confirmed osteoarticular TB should be treated with a four-drug regimen (HRZE) for 2 months, followed by a two-drug regimen (HR) for 10 months, the total duration of treatment being 12 months. (Strong recommendation, low certainty of evidence)"
        ],
        [
          "Streptomycin should not be used as part of first-line treatment regimens for children with pulmonary TB or tuberculous peripheral lymphadenitis. (Strong recommendation, moderate certainty of evidence)"
        ],
        [
          "WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-susceptible tuberculosis treatment, 2022 update (55)"
        ],
        [
          "New patients with pulmonary TB should receive a regimen containing 6 months of rifampicin: 2HRZE/4HR.³⁶ (Strong recommendation, high certainty of evidence)"
        ],
        [
          "In all patients with drug-susceptible pulmonary TB, the use of thrice-weekly dosing is not recommended in both the intensive and continuation phases of therapy, and daily dosing remains the recommended dosing frequency. (Conditional recommendation, very low certainty in the evidence)"
        ],
        [
          "The use of FDC tablets is recommended over separate drug formulations in treatment of patients with drug-susceptible TB. (Conditional recommendation, low certainty in the evidence)"
        ],
        [
          "In patients with tuberculous meningitis, an initial adjuvant corticosteroid therapy with dexamethasone or prednisolone tapered over 6–8 weeks should be used. (Strong recommendation, moderate certainty in the evidence)"
        ],
        [
          "Patients aged 12 years and older with drug-susceptible pulmonary TB, may receive a 4-month regimen of isoniazid, rifapentine, moxifloxacin and pyrazinamide. (NEW in DS-TB guidelines: Conditional recommendation, moderate certainty evidence)"
        ],
        [
          "WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment, 2020 update (9)"
        ],
        [
          "Regimen for rifampicin-susceptible and isoniazid-resistant tuberculosis"
        ],
        [
          "In patients with confirmed rifampicin-susceptible, isoniazid-resistant tuberculosis (Hr-TB), treatment with rifampicin, ethambutol, pyrazinamide and levofloxacin is recommended for a duration of 6 months. (Conditional recommendation, very low certainty in the estimates of effect)"
        ],
        [
          "In patients with confirmed rifampicin-susceptible, isoniazid-resistant tuberculosis, it is not recommended to add streptomycin or other injectable agents to the treatment regimen. (Conditional recommendation, very low certainty in the estimates of effect)"
        ],
        [
          "Shorter all-oral bedaquiline-containing regimen for multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB)"
        ],
        [
          "A shorter all-oral bedaquiline-containing regimen of 9–12 months duration is recommended in eligible patients with confirmed multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) who have not been exposed to treatment with second-line TB medicines used in this regimen for more than 1 month, and in whom resistance to fluoroquinolones has been excluded. (Conditional recommendation, very low certainty in the evidence in adults and adolescents)"
        ],
        [
          "Longer regimens for MDR- or RR-TB"
        ],
        [
          "In multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) patients on longer regimens, all three Group A agents and at least one Group B agent should be included to ensure that treatment starts with at least four TB agents likely to be effective, and that at least three agents are included for the rest of treatment if bedaquiline is stopped. If only one or two Group A agents are used, both Group B agents are to be included. If the regimen cannot be composed with agents from Groups A and B alone, Group C agents are added to complete it. (Conditional recommendation, very low certainty in the estimates of effect)"
        ],
        [
          "Kanamycin and capreomycin are not to be included in the treatment of MDR/RR-TB patients on longer regimens. (Conditional recommendation, very low certainty in the estimates of effect)"
        ],
        [
          "Levofloxacin or moxifloxacin should be included in the treatment of MDR/RR-TB patients on longer regimens. (Strong recommendation, moderate certainty in the estimates of effect)"
        ],
        [
          "Linezolid should be included in the treatment of MDR/RR-TB patients on longer regimens. (Strong recommendation, moderate certainty in the estimates of effect)"
        ],
        [
          "Clofazimine and cycloserine or terizidone may be included in the treatment of MDR/RR-TB patients on longer regimens. (Conditional recommendation, very low certainty in the estimates of effect)"
        ],
        [
          "Ethambutol may be included in the treatment of MDR/RR-TB patients on longer regimens. (Conditional recommendation, very low certainty in the estimates of effect)"
        ],
        [
          "Pyrazinamide may be included in the treatment of MDR/RR-TB patients on longer regimens. (Conditional recommendation, very low certainty in the estimates of effect)"
        ],
        [
          "Imipenem–cilastatin or meropenem may be included in the treatment of MDR/RR-TB patients on longer regimens.³⁷ (Conditional recommendation, very low certainty in the estimates of effect)"
        ],
        [
          "Amikacin may be included in the treatment of MDR/RR-TB patients aged 18 years or more on longer regimens when susceptibility has been demonstrated and adequate measures to monitor for adverse reactions can be ensured. If amikacin is not available, streptomycin may replace amikacin under the same conditions. (Conditional recommendation, very low certainty in the estimates of effect)"
        ],
        [
          "Ethionamide or prothionamide may be included in the treatment of MDR/RR-TB patients on longer regimens only if bedaquiline, linezolid, clofazimine or delamanid are not used, or if better options to compose a regimen are not possible. (Conditional recommendation against use, very low certainty in the estimates of effect)"
        ],
        [
          "P-aminosalicylic acid may be included in the treatment of MDR/RR-TB patients on longer regimens only if bedaquiline, linezolid, clofazimine or delamanid are not used, or if better options to compose a regimen are not possible. (Conditional recommendation against use, very low certainty in the estimates of effect)"
        ],
        [
          "Clavulanic acid should not be included in the treatment of MDR/RR-TB patients on longer regimens. (Strong recommendation against use, low certainty in the estimates of effect)"
        ],
        [
          "The bedaquiline, pretomanid and linezolid (BPaL) regimen for multidrug-resistant tuberculosis with additional fluoroquinolone resistance"
        ],
        [
          "A treatment regimen lasting 6–9 months, composed of bedaquiline, pretomanid and linezolid (BPaL), may be used under operational research conditions in multidrug-resistant tuberculosis (MDR-TB) patients with TB that is resistant to fluoroquinolones, who have either had no previous exposure to bedaquiline and linezolid or have been exposed for no more than 2 weeks. (Conditional recommendation, very low certainty in the estimates of effect) Note: this recommendation concerns patients aged 14 years and above."
        ],
        [
          "Monitoring patient response to MDR-TB treatment using culture"
        ],
        [
          "In multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) patients on longer regimens, the performance of sputum culture in addition to sputum smear microscopy is recommended to monitor treatment response. (Strong recommendation, moderate certainty in the estimates of test accuracy). It is desirable for sputum culture to be repeated at monthly intervals. Subgroup considerations: Patients <15 years of age with MDR/RR-TB comprised less than 2% of the IPD-MA analysed for PICO question 11 (MDR/RR-TB, 2018). Younger children usually cannot produce sufficient sputum spontaneously to allow a bacteriological diagnosis (many are typically sputum smear-microscopy negative). In these patients, culture may be a more sensitive means to detect viable TB bacilli even if very few organisms are present in the sputum or other samples, below the detection threshold of direct microscopy. However, in children who are unable to expectorate, gastric aspirates or induced sputa may be possible but the repetition of such tests at monthly frequency may not be acceptable."
        ]
      ],
      "notes": "³⁶ This recommendation is applicable to adolescents from 15 years of age ³⁷ Imipenem-cilastatin and meropenem are administered with clavulanic acid, which is available only in formulations combined with amoxicillin. Amoxicillin-clavulanic acid is not counted as an additional effective TB agent, and should not be used without imipenem- cilastatin or meropenem. [Transcriber: single-column table; rows include the source-guideline headings and topic subheadings as printed, followed by the recommendation cells.]",
      "narratives": {
        "en": "The table compiles current WHO recommendations on the treatment of TB relevant to children and adolescents, covering drug-susceptible TB regimens and drug-resistant TB regimens (isoniazid-resistant TB, shorter and longer MDR/RR-TB regimens, BPaL, and monitoring by culture). Recommendations are grouped by source guideline and topic, each with its strength and certainty of evidence.",
        "ar": "يجمع الجدول توصيات المنظمة الحالية بشأن علاج السل ذات الصلة بالأطفال والمراهقين، وتشمل نظم علاج السل الحساس للأدوية ونظم علاج السل المقاوم للأدوية (السل المقاوم للإيزونيازيد، والنظم القصيرة والطويلة للسل المقاوم للأدوية المتعددة/للريفامبيسين، ونظام BPaL، والرصد بالمزرعة). والتوصيات مصنفة حسب المبدأ التوجيهي المصدر والموضوع، مع بيان قوة كل توصية ودرجة اليقين في البيّنات.",
        "zh": "本表汇集与儿童和青少年相关的现行世卫组织结核病治疗建议，涵盖药物敏感结核病治疗方案和耐药结核病治疗方案（耐异烟肼结核病、耐多药/利福平耐药结核病短程和长程方案、BPaL方案以及培养监测）。建议按来源指南和主题分组，并注明每项建议的强度和证据确定性。",
        "es": "El cuadro reúne las recomendaciones vigentes de la OMS sobre el tratamiento de la tuberculosis pertinentes para niños y adolescentes, que abarcan las pautas para la tuberculosis farmacosensible y para la farmacorresistente (tuberculosis resistente a la isoniazida, pautas cortas y largas para la TB-MDR/RR, BPaL y seguimiento mediante cultivo). Se agrupan por directriz de origen y tema, cada una con su fuerza y la certeza de la evidencia.",
        "fr": "Le tableau rassemble les recommandations actuelles de l’OMS sur le traitement de la tuberculose concernant les enfants et les adolescents, couvrant les schémas pour la tuberculose pharmacosensible et pour la tuberculose pharmacorésistante (tuberculose résistante à l’isoniazide, schémas courts et longs pour la tuberculose MR/RR, BPaL et suivi par culture). Elles sont regroupées par ligne directrice source et par thème, avec leur force et le degré de certitude des données.",
        "ru": "В таблице собраны действующие рекомендации ВОЗ по лечению туберкулеза, касающиеся детей и подростков, включая схемы лечения лекарственно-чувствительного и лекарственно-устойчивого туберкулеза (туберкулез, устойчивый к изониазиду, короткие и длительные схемы при МЛУ/РУ-ТБ, BPaL и мониторинг с помощью посева). Рекомендации сгруппированы по исходному руководству и теме с указанием их силы и степени достоверности данных."
      },
      "csv": "tables/table-6.csv"
    },
    {
      "label": "Table 7",
      "caption": "Table 7: WHO recommendations on models of TB care relevant to children and adolescents",
      "pages": [
        87,
        88
      ],
      "columns": [
        {
          "titles": ""
        }
      ],
      "rows": [
        [
          "WHO consolidated guidelines on tuberculosis. Module 4: treatment – care and support during tuberculosis treatment (100)"
        ],
        [
          "Health education and counselling on the disease and treatment adherence should be provided to patients on TB treatment. (Strong recommendation, moderate certainty in the evidence)"
        ],
        [
          "A package of treatment adherence interventions³⁸ may be offered for patients on TB treatment in conjunction with the selection of a suitable treatment administration option.³⁹ (Conditional recommendation, low certainty in the evidence)"
        ],
        [
          "One or more of the following treatment adherence interventions (complementary and not mutually exclusive) may be offered to patients on TB treatment or to health care providers: a. tracers⁴⁰ or digital medication monitor⁴¹ (Conditional recommendation, very low certainty in the evidence) b. material support to the patient⁴² (Conditional recommendation, moderate certainty in the evidence); c. psychological support to the patient⁴³ (Conditional recommendation, low certainty in the evidence) d. staff education⁴⁴ (Conditional recommendation, low certainty in the evidence)."
        ],
        [
          "The following treatment administration options may be offered to patients on TB treatment: a. Community- or home-based treatment support is recommended over health facility-based treatment support or unsupported treatment (conditional recommendation, moderate certainty in the evidence); b. Treatment support administered by trained lay providers or health care workers is recommended over treatment support administered by family members or unsupported treatment (conditional recommendation, very low certainty in the evidence) c. Video supported treatment (VST) can replace treatment support when the video communication technology is available and can be appropriately organized and operated by health-care providers and patients (conditional recommendation, very low certainty in the evidence)."
        ],
        [
          "Patients with multidrug-resistant TB (MDR-TB) should be treated using mainly ambulatory care rather than models of care based principally on hospitalization. (Conditional recommendation, very low certainty evidence)"
        ],
        [
          "A decentralized model of care is recommended over a centralized model for patients on MDR-TB treatment. (Conditional recommendation, very low certainty in the evidence)"
        ]
      ],
      "notes": "³⁸ Treatment adherence interventions include social support such as patient education and counselling, material support (e.g. food, financial incentive, and transport fee); psychological support; tracers such as home visit or digital health communication (e.g. SMS, telephone call); medication monitor; and staff education. The interventions should be selected on the basis of the assessment of individual patient’s needs, provider’s resources and conditions for implementation. ³⁹ Suitable treatment administration options include various forms of treatment support, such as video-supported treatment and regular community of home-based treatment support. ⁴⁰ Tracers refer to communication with the patient including via SMS, telephone (voice) calls, or home visit. ⁴¹ A digital medication monitor is a device that can measure the time between openings of the pill box. The medication monitor may have audio reminders or send an SMS to remind patient to take medications, along with recording when the pill box is opened. ⁴² Material support can be food or financial support such as: meals, food baskets, food supplements, food vouchers, transport subsidies, living allowance, housing incentives, or financial bonus. This support addresses indirect costs incurred by patients or their attendants in order to access health services, and possibly tries to mitigate consequences of income loss related to the disease. ⁴³ Psychological support can be counselling sessions or peer-group support. ⁴⁴ Staff education can be adherence education, chart or visual reminder, educational tools and desktop aids for decision-making and reminder. [Transcriber: single-column table; rows include the source-guideline headings and topic subheadings as printed, followed by the recommendation cells.]",
      "narratives": {
        "en": "The table compiles current WHO recommendations on models of TB care relevant to children and adolescents, taken from the guidelines on care and support during TB treatment. They cover health education and counselling, treatment adherence interventions, treatment administration options, ambulatory care and decentralized care for MDR-TB, each with its strength and certainty of evidence.",
        "ar": "يجمع الجدول توصيات المنظمة الحالية بشأن نماذج رعاية مرضى السل ذات الصلة بالأطفال والمراهقين، والمستمدة من المبادئ التوجيهية بشأن الرعاية والدعم أثناء علاج السل. وتشمل التثقيف الصحي والمشورة، وتدخلات الالتزام بالعلاج، وخيارات إعطاء العلاج، والرعاية الخارجية واللامركزية لمرضى السل المقاوم للأدوية المتعددة، مع بيان قوة كل توصية ودرجة اليقين في البيّنات.",
        "zh": "本表汇集与儿童和青少年相关的现行世卫组织结核病医护模式建议，取自结核病治疗期间关怀和支持指南。内容涵盖健康教育和咨询、治疗依从性干预措施、治疗给药方式、耐多药结核病门诊治疗和分散式医护，并注明每项建议的强度和证据确定性。",
        "es": "El cuadro reúne las recomendaciones vigentes de la OMS sobre modelos de atención de la tuberculosis pertinentes para niños y adolescentes, tomadas de las directrices sobre atención y apoyo durante el tratamiento. Abarcan la educación sanitaria y el asesoramiento, las intervenciones de adherencia, las opciones de administración del tratamiento y la atención ambulatoria y descentralizada de la TB-MDR, cada una con su fuerza y la certeza de la evidencia.",
        "fr": "Le tableau rassemble les recommandations actuelles de l’OMS sur les modèles de soins antituberculeux concernant les enfants et les adolescents, tirées des lignes directrices sur les soins et le soutien pendant le traitement. Elles portent sur l’éducation sanitaire et le conseil, les interventions favorisant l’observance, les modalités d’administration du traitement, et les soins ambulatoires et décentralisés de la tuberculose multirésistante, avec leur force et le degré de certitude des données.",
        "ru": "В таблице собраны действующие рекомендации ВОЗ по моделям оказания помощи при туберкулезе, касающиеся детей и подростков, из руководства по уходу и поддержке во время лечения туберкулеза. Они охватывают санитарное просвещение и консультирование, меры по повышению приверженности лечению, варианты приема лечения, амбулаторное и децентрализованное лечение МЛУ-ТБ с указанием силы каждой рекомендации и степени достоверности данных."
      },
      "csv": "tables/table-7.csv"
    },
    {
      "label": "Table 8",
      "caption": "Table 8: WHO recommendations on TB/HIV coinfection and nutrition relevant to children and adolescents",
      "pages": [
        89,
        90,
        91,
        92
      ],
      "columns": [
        {
          "titles": ""
        }
      ],
      "rows": [
        [
          "WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders, 2012 (124)"
        ],
        [
          "Routine HIV testing should be offered to all patients with presumptive and diagnosed TB. (Strong recommendation, low certainty of evidence)"
        ],
        [
          "Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach, July 2021 (125)"
        ],
        [
          "Co-trimoxazole prophylaxis for infants, children and adolescents living with HIV"
        ],
        [
          "Co-trimoxazole prophylaxis is recommended for infants, children and adolescents with HIV, regardless of clinical and immune conditions. Priority should be given to all children younger than 5 years old regardless of CD4 cell count or clinical stage and children with severe or advanced HIV clinical disease (WHO clinical stage 3 or 4) and/or those with CD4 cell count ≤350 cells/mm³. (Strong recommendation, high certainty evidence)"
        ],
        [
          "In settings where malaria and/or severe bacterial infections are highly prevalent, co-trimoxazole prophylaxis should be continued until adulthood, irrespective of whether ART is provided. (Conditional recommendation, moderate certainty evidence)"
        ],
        [
          "In settings with low prevalence for both malaria and bacterial infections, cotrimoxazole prophylaxis may be discontinued for children 5 years of age and older who are clinically stable and/or virally suppressed on ART for at least six months and with a CD4 count >350 cells/mm³. (Strong recommendation, very low certainty evidence)."
        ],
        [
          "Co-trimoxazole prophylaxis is recommended for HIV-exposed infants from 4 to 6 weeks of age and should be continued until HIV infection has been excluded by an age-appropriate HIV test to establish final diagnosis after complete cessation of breastfeeding. (Strong recommendation, very low certainty evidence)"
        ],
        [
          "Routine co-trimoxazole prophylaxis should be given to all people living with HIV with TB disease regardless of CD4 cell count. (Strong recommendation, high certainty evidence)"
        ],
        [
          "General recommendations on eligibility for ART"
        ],
        [
          "ART should be initiated for all people living with HIV regardless of WHO clinical stage and at any CD4 cell count. • Pregnant and breastfeeding women (strong recommendation, moderate certainty evidence) • Adolescents (conditional recommendation, low certainty evidence) • Children living with HIV, one year old to less than 10 years old (conditional recommendation, low certainty evidence) • Infants diagnosed in the first year of life (strong recommendation, moderate certainty evidence)"
        ],
        [
          "Rapid ART initiation should be offered to all people living with HIV following a confirmed HIV diagnosis and clinical assessment. (Strong recommendation, high-certainty evidence for adults and adolescents; low certainty evidence for children). Rapid initiation is defined as within seven days from the day of HIV diagnosis; people with advanced HIV disease should be given priority for assessment and initiation."
        ],
        [
          "ART initiation should be offered on the same day to people who are ready to start. (Strong recommendation, high certainty evidence for adults and adolescents; low certainty evidence for children)"
        ],
        [
          "Timing of ART for children and adolescents with TB"
        ],
        [
          "ART should be started as soon as possible within 2 weeks of initiating TB treatment, regardless of CD4 count, among adolescents and children living with HIV (except when signs and symptoms of meningitis are present). (Adolescents: strong recommendation, low- to moderate-certainty evidence; Children and infants: strong recommendation, very low certainty evidence) ART should be delayed at least 4 weeks (and initiated within 8 weeks) after treatment for TB meningitis is initiated."
        ],
        [
          "First-line ART regimens"
        ],
        [
          "Dolutegravir (DTG) in combination with a nucleoside reverse-transcriptase inhibitor (NRTI) backbone is recommended as the preferred first-line regimen for people living with HIV initiating ART • Adolescents (strong recommendation, moderate certainty evidence) • Infants and children with approved DTG dosing (conditional recommendation, low certainty evidence)"
        ],
        [
          "A raltegravir (RAL)-based regimen may be recommended as the preferred first-line regimen for neonates (Conditional recommendation, very low certainty evidence)"
        ],
        [
          "Second-line ART regimens"
        ],
        [
          "DTG in combination with an optimized NRTI backbone may be recommended as a preferred second-line regimen for people living with HIV for whom non-DTG-based regimens are failing. • Adolescents (conditional recommendation, moderate certainty evidence) • Children with approved DTG dosing (conditional recommendation, low certainty evidence)"
        ],
        [
          "Boosted protease inhibitors in combination with an optimized NRTI backbone are recommended as a preferred second-line regimen for people living with HIV for whom DTG-based regimens are failing. (Strong recommendation, moderate certainty evidence)"
        ],
        [
          "Guidelines: updates on the management of severe acute malnutrition in infants and children, 2013 (60)"
        ],
        [
          "Infants with severe acute malnutrition who are admitted for inpatient care should be given parenteral antibiotics to treat possible sepsis and appropriate treatment for other medical complications such as tuberculosis, HIV, surgical conditions or disability. (Strong recommendation, very low certainty evidence)"
        ],
        [
          "Guideline: nutritional care and support for patients with tuberculosis, 2013 (126)"
        ],
        [
          "Management of severe acute malnutrition"
        ],
        [
          "School-age children and adolescents (5 to 19 years), and adults, including pregnant and lactating women, with TB disease and severe acute malnutrition (very low BMI-for-age) should be treated in accordance with the WHO recommendations for management of severe acute malnutrition. (Strong recommendation, very low certainty evidence)"
        ],
        [
          "Children who are less than 5 years of age with TB disease and severe acute malnutrition (mid-upper arm circumference more than 115 mm or weight-for-height/length more than three z-scores below the WHO child growth standards median, or with any degree of bilateral pitting oedema) should be treated in accordance with the WHO recommendations for the management of severe acute malnutrition in children who are less than 5 years of age. (Strong recommendation, very low certainty evidence)"
        ],
        [
          "Management of moderate undernutrition"
        ],
        [
          "School-age children and adolescents (5 to 19 years) and adults, including lactating women, with TB disease and moderate undernutrition, who fail to regain normal body mass index after 2 months’ TB treatment, as well as those who are losing weight during TB treatment, should be evaluated for adherence and comorbid conditions. They should also receive nutrition assessment and counselling and if indicated be provided with locally available nutrient-rich or fortified supplementary foods as necessary to restore normal nutritional status. (Conditional recommendation, low certainty evidence)"
        ],
        [
          "Children who are less than 5 years of age with TB disease and moderate undernutrition should be managed as any other children with moderate undernutrition. This includes provision of locally available nutrient-rich or fortified supplementary foods, in order to restore appropriate weight-for-height. (Strong recommendation, very low certainty evidence)"
        ],
        [
          "Patients with multidrug-resistant TB and moderate undernutrition should be provided with locally available nutrient-rich or fortified supplementary foods, as necessary, to restore normal nutritional status. (Strong recommendation, very low certainty evidence)"
        ],
        [
          "A daily multiple micronutrient supplement at 1× recommended nutrient intake should be provided in situations where fortified or supplementary foods should have been provided in accordance with standard management of moderate undernutrition,⁴⁵ but are unavailable. (Conditional recommendation, very low certainty evidence)"
        ],
        [
          "Nutrition screening as part of contact investigation"
        ],
        [
          "In settings where contact tracing is implemented, household contacts of people with TB disease should have a nutrition screening and assessment as part of contact investigation. If malnutrition is identified, it should be managed according to WHO recommendations. (Conditional recommendation, very low certainty evidence) Remarks: • There is no evidence that nutritional management of acute malnutrition of patients with TB disease should be different than for those without TB. • Concerns about weight loss or failure to gain weight should trigger further clinical assessment (e.g. resistance to TB drugs, poor adherence, comorbid conditions) and nutrition assessment, in order to determine the most appropriate interventions. • Closer nutritional monitoring and earlier initiation of nutrition support (before the first 2 months of TB treatment are completed) should be considered if the nutritional indicator is approaching the cut-off value for a diagnosis of severe undernutrition."
        ]
      ],
      "notes": "⁴⁵ Pyridoxine supplementation is recommended along with isoniazid treatment for all pregnant (or breastfeeding) women, as well as for people with conditions such as HIV infection, alcohol dependency, malnutrition, diabetes, chronic liver disease or renal failure. Pyridoxine provision together with isoniazid treatment was not analysed for the 2013 nutrition guideline. [Transcriber: single-column table; rows include the source-guideline headings and topic subheadings as printed, followed by the recommendation cells.]",
      "narratives": {
        "en": "The table compiles current WHO recommendations relevant to children and adolescents on TB/HIV coinfection (HIV testing, co-trimoxazole prophylaxis, eligibility for and timing of ART, first- and second-line ART regimens) and on nutrition (severe acute malnutrition, moderate undernutrition and nutrition screening of contacts). Recommendations are grouped by source guideline and topic, each with its strength and certainty of evidence.",
        "ar": "يجمع الجدول توصيات المنظمة الحالية ذات الصلة بالأطفال والمراهقين بشأن العدوى المصاحبة بالسل وفيروس العوز المناعي البشري (اختبار الفيروس، والوقاية بالكوتريموكسازول، والأهلية للعلاج بمضادات الفيروسات القهقرية وتوقيته، ونظم الخط الأول والثاني) وبشأن التغذية (سوء التغذية الحاد الوخيم، ونقص التغذية المعتدل، وتحري التغذية لدى المخالطين). والتوصيات مصنفة حسب المبدأ التوجيهي المصدر والموضوع، مع بيان قوة كل توصية ودرجة اليقين في البيّنات.",
        "zh": "本表汇集与儿童和青少年相关的现行世卫组织建议，涉及结核病/艾滋病毒合并感染（艾滋病毒检测、复方新诺明预防、抗逆转录病毒治疗的适用条件和时机、一线和二线抗逆转录病毒治疗方案）以及营养（重度急性营养不良、中度营养不足和接触者营养筛查）。建议按来源指南和主题分组，并注明每项建议的强度和证据确定性。",
        "es": "El cuadro reúne las recomendaciones vigentes de la OMS pertinentes para niños y adolescentes sobre la coinfección TB/VIH (pruebas del VIH, profilaxis con cotrimoxazol, criterios y momento de inicio del TAR, pautas de TAR de primera y segunda línea) y sobre nutrición (malnutrición aguda grave, desnutrición moderada y cribado nutricional de los contactos). Se agrupan por directriz de origen y tema, cada una con su fuerza y la certeza de la evidencia.",
        "fr": "Le tableau rassemble les recommandations actuelles de l’OMS concernant les enfants et les adolescents sur la co-infection tuberculose/VIH (dépistage du VIH, prophylaxie par le cotrimoxazole, critères et moment d’instauration du TAR, schémas de TAR de première et de deuxième intention) et sur la nutrition (malnutrition aiguë sévère, dénutrition modérée et dépistage nutritionnel des contacts). Elles sont regroupées par ligne directrice source et par thème, avec leur force et le degré de certitude des données.",
        "ru": "В таблице собраны действующие рекомендации ВОЗ, касающиеся детей и подростков, по сочетанной инфекции ТБ/ВИЧ (тестирование на ВИЧ, профилактика ко-тримоксазолом, показания и сроки начала АРТ, схемы АРТ первого и второго ряда) и по питанию (тяжелая острая недостаточность питания, умеренная недостаточность питания и скрининг питания контактов). Рекомендации сгруппированы по исходному руководству и теме с указанием их силы и степени достоверности данных."
      },
      "csv": "tables/table-8.csv"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 33,
      "note": "outline"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 34,
      "note": "2 levels"
    },
    {
      "kind": "figures",
      "state": "partial",
      "count": 1,
      "note": "2 captioned in the text"
    },
    {
      "kind": "tables",
      "state": "found",
      "count": 8
    },
    {
      "kind": "references",
      "state": "not-extracted",
      "note": "a references section is in the text (p97); its entries are not extracted"
    },
    {
      "kind": "glossary",
      "state": "not-extracted",
      "note": "a glossary section is in the text (p11); its entries are not extracted"
    },
    {
      "kind": "footnotes",
      "state": "not-extracted"
    },
    {
      "kind": "summaries",
      "state": "partial",
      "count": 32,
      "note": "32 of 34 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-352522"
  }
}
